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ABSTRACT 
   Apoptosis or programmed cell death plays an important role in the regulation of B cell survival. 
Failures in the apoptotic signaling can lead to autoimmune diseases or cancer.  Moreover, apoptosis 
is a major mode of cell death in cancer therapy, and resistance to therapy is often associated with 
disturbances in the apoptotic signaling. The detailed knowledge of the apoptotic signaling pathways 
can be used as an advantage in the development of new treatment modalities against B cell 
malignancies. Two major signaling pathways leading to apoptosis have been described. The 
extrinsic pathway is commonly triggered by activation of death receptors, such as Fas/CD95, and 
involves the activation of the cysteine protease caspase-8. The intrinsic pathway is initiated by 
various extracellular or intracellular stress signals, which induce changes in mitochondrial 
membrane permeability and trigger the activation of the caspase-9. The initiator-caspases -8 or -9 
activate the cascade of downstream caspases, which are responsible for organized degradation of 
cellular organelles.  
   During adaptive immune response, B cells are selected based on their affinity for foreign antigens, 
such as surface molecules of bacteria. The selection of antigen activated B cells takes place at the 
germinal centers (GC) of lymphoid organs, and is regulated by surface receptors including B-cell 
receptor (BCR), Fas/CD95 and CD40. In this study, BCR- and Fas -induced apoptosis of follicular 
lymphoma cells was inhibited by CD40 stimulation. BCR-induced apoptosis involved the 
mitochondrial breach and caspase-9 activation pathway, while in Fas-induced apoptosis caspases-8 
and -3 were activated independently of mitochondria. The CD40-mediated protection against Fas-
induced apoptosis was associated with a rapid and NF-κB-dependent up-regulation of c-FLIP 
proteins, natural inhibitors of caspase-8 activation.  Based on our findings, BCR-induced apoptosis 
may be involved in the deletion of self-reactive cells generated during the GC reaction, while Fas-
induced apoptosis may be involved in the deletion of low affinity B cells. 
   Follicular lymphoma is a cancer that originates from GC B cells. The second aim of this study was 
to explore signaling pathways of apoptosis induced by rituximab, a chimeric monoclonal antibody 
used for the treatment of B cell lymphomas. Rituximab-mediated apoptosis of follicular lymphoma 
cells was dependent on the activation of caspase-9 and mitochondrial breach, while the death 
receptor pathway was not involved. Moreover, the simultaneous triggering of Fas enhanced 
significantly apoptosis induced by rituximab. Thus, the combined use of rituximab with drugs 
designed to destabilize mitochondrial membranes, or with drugs that induce the activation of the 
death receptor pathway, is warranted for further investigation in clinical settings.  
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Transduction; Caspases; Caspase 8; Caspase 9; Mitochondria; Mitochondrial Membranes; 
Receptors, Antigen, B-Cell; Antigens, CD95; Antigens, CD40; NF-kappa B; CASP8 and FADD-
Like Apoptosis Regulating Protein; Antibodies, Monoclonal; Receptors, Death Domain; 
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PKC protein kinase c 
TNF tumor necrosis factor 
TRAIL tumor necrosis factor-related apoptosis inducing ligand 
TRAF tumor necrosis factor associating factor 
zVAD benzyloxycarbonyl-Val-Ala-Asp 
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1. INTRODUCTION 
 
   In our body, millions of cells are being produced every day. To maintain homeostasis, the 
divisions of cells must be delicately balanced by deletion of unnecessary cells. Elegantly, these cells 
are cleared by a tightly regulated process called apoptosis or programmed cell death.  
   Apoptosis is genetically regulated form of cell death, in which a single cell is sacrificed for the 
benefit for the whole organisms. There are several circumstances in which multicellular organisms 
benefit for the targeted deletion of cells. For example, cells irreversibly injured by virus infection, 
radiation, growth factor withdrawal or other violating signals from outside of the cell are no longer 
useful for the organism and thus eliminated. In addition, various stress signals originating from 
inside of the cell, such as DNA lesions that have occurred during cell divisions, can induce 
programmed cell death. Unfortunately, some of the cells which have gained abnormalities in genes 
regulating apoptosis may escape from cell death and continue to proliferate. These cells are 
potentially hazardous, since the further accumulation of growth promoting and apoptosis inhibiting 
lesions can in rare circumstances lead to development of cancer, a disease characterized by 
uncontrolled cell proliferation. 
   Follicular lymphoma (FL) is a heterogeneous cancer disease of B cell origin. In Finland, over two 
hundred follicular lymphoma cases are diagnosed annually. Until these days, this disease has been 
assumed as incurable, and thus only the patients with symptoms or with advanced disease are 
treated with standard chemotherapy. However, immunotherapy with anti-CD20 antibody rituximab 
has recently improved the overall survival and disease free time of FL patients when combined to 
standard chemotherapy. When given to patients, rituximab depletes B cells by three overlapping 
mechanisms; complement-mediated cytotoxicity, antibody-dependent cytotoxicity and apoptosis. 
Thus far, the molecular mechanisms of rituximab-induced apoptosis are largely unsolved. The great 
advantage of rituximab and also other therapies based on the use of immunotherapeutic antibodies is 
their specificity for the cancer cells and thus milder side effects as compared to standard 
chemotherapies. Inspired by rituximab, several immunotherapeutic drugs are currently under 
clinical or preclinical trials for the treatment of B cell lymphomas and also for other cancer diseases.  
   Study of apoptotic signaling pathways is important, since these pathways are potential targets 
when developing new treatment modalities for cancer. Commonly, cancer is associated with 
dysregulation of apoptotic pathways, which offers targets for drug discovery. Majority of cancer 
therapeutics used currently delete cancer cells by apoptosis. Thus, failures in apoptotic signaling can 
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result in the resistance against cancer therapy, which may be hindered by drugs promoting 
apoptosis. This work was aimed to reveal the molecular mechanisms involved in the receptor-
mediated apoptosis of B cells. Apoptotic pathways induced by B cell receptor and Fas are important 
regulators of B cell fate during B cell development and immune reactions. The molecular 
mechanisms of CD20-induced cell death are currently unknown despite the wide use of anti-CD20 
antibody rituximab in the immunotherapy. This work proposes signaling pathways involved in 
BCR, Fas and CD20 –mediated apoptosis in a FL cell line. The detailed knowledge of the apoptotic 
signaling pathways may be used in the future for the development of novel, apoptosis directed 
treatment modalities against cancer diseases. 
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2. REVIEW OF THE LITERATURE  
 
2.1. Apoptosis 
2.1.1 Different ways to die; apoptosis, autophagy and necrosis  
   In the human body dazzling rate of continuous cell division must be compensated by cell death to 
maintain tissue homeostasis. Either deficient or excessive cell death can lead to a variety of 
pathologic conditions.  For example, insufficient death of cells with deleterious genetic lesions may 
result in the development of cancer. Conversely, ischemia induced cell death during stroke or 
myocardial infarction incurs irreversible tissue damage. 
   Cell death can be classified according to morphological appearance, biochemical patterns and 
functional aspects (programmed versus accidental) (Galluzzi et al., 2007). Mainly based on the 
morphological features, three different forms of cell death can be classified; apoptosis, autophagy 
and necrosis. However, in some instances the dying cell has overlapping features of different cell 
death modalities making the exact classification unfeasible. 
   Apoptosis or programmed cell death (type I cell death) is genetically engineered, physiological 
form of cell death where the single cell is sacrificed for the benefit for the whole organism. The 
term apoptosis was first introduced in the 1970`s century by Kerr and Wyllie, who first described 
the cell death with specific morphological features (Kerr et al., 1972). These well defined 
morphological changes include cell shrinkage and nuclear condensation (pyknosis), nuclear 
fragmentation (karyohexis) and plasma membrane blebbing (Galluzzi et al., 2007). Finally the intact 
cytoplasmic organelles or fragments of the nucleus are cleanly packaged inside membrane bounded 
vacuoles which are also called apoptotic bodies. Eventually, these apoptotic bodies are recognized 
and engulfed by phagocytic cells, without evoking an inflammatory response which could be 
harmful for the surrounding tissue. Apoptotic cell death is most often associated with typical 
biochemical events including DNA fragmentation, cysteine protease activation and mitochondrial 
membrane potential collapse, but these events are not definitive for apoptosis (Galluzzi et al., 2007). 
   Autophagy (type II cell death) is a process where parts of the cytoplasm are sequestered within 
double-membrane vacuoles and finally digested by lysosomal hydrolases (Kroemer and Jäättelä, 
2005). Autodigestion of cellular constituents may serve as a defense mechanism against nutrient 
deficiency or sub-lethal cellular injury and therefore autophagy may even prevent the cell death in 
some conditions. However, extensive autodigestion may lead to cell death especially in the cases 
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where apoptosis is somehow disturbed. The morphological hallmarks of autophagy include the 
double-membrane autophagic vacuoles and the lack of chromatin condensation and other typical 
features of apoptosis (Galluzzi et al., 2007). 
   Necrosis (type III cell death) is usually defined as a harmful event as it is often associated with 
pathological conditions involving excessive cell loss, and the disadvantage of necrotic cells to 
promote inflammatory response (Galluzzi et al., 2007). The necrotic cells undergo extensive 
swelling and unorganized dismantling of cytoplasmic organelles which eventually leads to the 
rupture of plasma membrane and spilling of the cell contents to surrounding extracellular space. 
Necrosis lacks the typical morphological characteristics of apoptosis and massive vacuolization seen 
during autophagic cell death. Necrosis is most often accompanied with the mitochondrial 
dysfunction including extensive production of reactive oxygen species, mitochondrial membrane 
permeabilization (MMP), ATP depletion and failure in Ca
2+
 homeostasis. The activation of calpain 
and cathepsin proteases and the lysosomal rupture are typically observed during the necrotic cell 
death. While sufficient ATP and glucose content are obligatory for apoptosis, their depletion favors 
switching to necrosis. However, the view that apoptosis is the only physiological or advantageous 
form of cell death whereas necrosis is always harmful and pathological process has recently gained 
a momentum. Indeed, apoptotic cell death can be shifted to necrosis in the circumstances where the 
activation of caspase-activation is artificially blocked (Goldstein et al., 2005). In addition, in some 
instances necrosis can be programmed and triggered appropriately by specific plasma membrane 
receptors, although these characteristics of cell death have been previously associated only with 
apoptotic cell death (Galluzzi et al., 2007). Thus, there is marked overlap between the different cell 
deaths, and in many cases features of different forms of cell death can be observed simultaneously. 
   The next chapters are focused on the detailed examination of apoptotic signaling pathways.  In 
general, there are two main apoptotic pathways, the extrinsic and intrinsic pathways, which differ in 
their inducing agent and the involvement of mitochondria (Figure 1.). Both of these pathways lead 
to the activation of a series of cysteine proteases called caspases, which are activated in a cascade in 
which activated caspases cleave and activate downstream caspases (Boatright and Salvesen, 2003). 
The extrinsic pathway is commonly triggered by activation of death receptors, such as Fas/CD95, 
and involves the activation of the cysteine protease caspase-8. The intrinsic pathway is initiated by 
various extracellular or intracellular stress signals, which induce changes in mitochondrial 
membrane permeability and trigger the activation of the caspase-9. In both pathways, the initiator-
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caspases activate the cascade of caspases, which are responsible for proteolysis of the cell 
constituents.    
Figure 1. The extrinsic and intrinsic apoptotic signaling pathways 
The extrinsic pathway is initiated by ligation of death receptors belonging to TNF-receptor 
superfamily (TNFR1, Fas/CD95, TRAIL-R1/R2). The intrinsic pathway is triggered as a result of 
stress signals that converge on the level of mitochondria. Both pathways result on the activation of 
executor caspases (caspase-3 and -7) which are responsible for the targeted proteolysis during the 
apoptotic cell death. 
2.1.2 Mitochondrial changes during apoptosis 
   Mitochondria are essential for life as they are responsible for oxidative energy production. In 
addition, mitochondria are centrally involved in the regulation of cell death. Mitochondria contain a 
highly folded inner membrane (IM) which is involved in the ion transport and energy production 
and an outer membrane (OM) which sequesters the intermembrane space (IMS) from the cytosol. 
Stress stimuli 
Bax/Bak 
Bcl-2 
Bcl-XL 
Mitochondria 
Apoptosis 
FLIP 
Apaf Cyt-c Cyt-c 
Smac 
HtrA2 
IAPs 
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B) Intrinsic pathway 
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Caspase-8 
Bid 
Caspase-3 
Caspase-9 
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   Variety of lethal signals from the endoplasmic reticulum, cell surface receptors, nucleus or 
extracellular environment converges on mitochondria to induce the mitochondrial outer membrane 
permeabilization (MOMP). As a result of MOMP, caspase-activating molecules, such as 
cytochrome c, and caspase-independent death effectors are released from the intermembrane space 
of mitochondria to the cytosol (Figure 1.). The permeabilization of the outer mitochondrial 
membrane is frequently associated with the permeabilization of the inner mitochondrial membrane, 
which leads to the collapse of mitochondrial membrane potential (ΔΨm), metabolic failure and 
eventually cell death. 
   The permeabilization of mitochondrial outer membrane is regulated by Bcl-2 family proteins and 
is considered as “point of no return” in apoptosis (Garrido et al., 2006; Green and Kroemer, 2004).  
The Bcl-2 family proteins are divided into two main groups according to their capacity to either 
inhibit or promote apoptosis (Kuwana and Newmeyer, 2003) (Figure 2.). The pro-apoptotic family 
members are further classified according to whether they have multiple Bcl-2 homology (BH) 
domains or only one BH domain (BH3-only proteins). The common feature of Bcl-2 family proteins 
is the formation of homo- or heterodimers with other family members thus neutralizing the action of 
each other.  
   Several pieces of evidence demonstrate that MOMP is a central event during apoptosis, and that 
the permeabilization process is precisely regulated by the Bcl-2 family proteins. Firstly, anti-
apoptotic Bcl-2 and Bcl-xL block the release of pro-apoptotic molecules from the intermembrane 
space and thus inhibit apoptosis (Kluck et al., 1997; Kuwana et al., 2002; Yang et al., 1997). 
Secondly, the pro-apoptotic Bcl-2 family members can permeabilize lipid bilayers, allowing the 
release of macromolecules across the membrane. The first clues that the Bcl-2 family proteins can 
permeabilize lipid membranes come from their structure, which has similarities with pore forming 
bacterial toxins (Suzuki et al., 2000).  Afterwards, it has been shown that oligomerized Bax can 
form channels in plain liposomes through which cytochrome c could be released (Saito et al., 2000). 
Moreover, it has been demonstrated that BH3 only protein Bid activates Bax to produce membrane 
openings in mitochondrial outer membrane large enough to transmit mitochondrial IMS proteins 
(Kuwana et al., 2002). This process could be inhibited by Bcl-xL and involved cardiolipin, an 
abundant lipid in the mitochondrial membrane. These findings were reproduced in cell models since 
it was found that cells lacking both Bax and Bak were completely resistant to cytochrome c release 
and apoptosis induced by activated Bid (Wei et al., 2001). Thus, it is now widely accepted that 
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during apoptosis, Bax and Bak oligomerize and insert on the mitochondrial outer membrane 
resulting in its permeabilization and the release of pro-apoptotic proteins from IMS to cytosol. 
 
Mitochondrial outer membrane permeabilization (MOMP) is regulated by the Bcl-2 family 
proteins 
Figure 2. The Bcl-2 family of proteins 
The Bcl-2 family of proteins is divided on three groups based on their composition of Bcl-2 
homology (BH) domains. The anti-apoptotic members contain four domains (BH1-4). The pro-
apoptotic members are divided in to two groups; multidomain proteins (Bax, Bak) which contain 
three domains (BH1-3), and the BH3-only proteins. Often, the BH3-only are subdivided into direct 
activators (Bid, BIM) and de-repressors/ sensitizers. Each protein contains the hydrophobic 
carboxyl terminal transmembrane domain (TM). 
 
 
  Inactive Bax exist in the cytosol as monomers whereas Bak is constitutively bound in 
mitochondrial outer membranes (Hsu and Youle, 1998; Youle and Strasser, 2008). It is generally 
believed that the activation of Bax/Bak involves the translocation of Bax to outer membrane and 
oligomerization with Bak to form membrane spanning pores. The activation of Bax/Bak is induced 
either directly or indirectly by “activator” BH3-only proteins, including Bid and Bim. According to 
“direct activation model”, BH3-only proteins (i.e. Bid and Bim) bind directly to Bax/Bak leading to 
their activation (Kim et al., 2006). According to an alternative “indirect activation model”, BH3-
Anti-apoptotic Bcl-2 proteins 
Pro-apoptotic Bcl-2 proteins 
Multiple BH3 domains 
BH3-only 
Bcl-2, Bcl-w, Bcl-XL, Mcl-1, A1 
Bax, Bak 
Bid, Bim 
Bad, Bik, Bmf, Hrk, Noxa, Puma 
BH4 BH3 BH1 BH2 
BH3 BH1 BH2 
TM 
TM 
TM BH3 
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only proteins promote apoptosis exclusively by binding and neutralizing anti-apoptotic Bcl-2 family 
members and thus unleashing Bax and Bak from their control. This model is supported by the 
findings that Bax and Bak do not bind to “activating” BH3-only proteins, and apoptosis proceed 
normally in cells deficient of Bim and Bid (Willis et al., 2007). The interactions between different 
Bcl-2 family members are still not fully elucidated and different set of these proteins depending on 
the cell type or an apoptosis inducing agent may be involved. 
 
The mitochondrial permeability transition and the membrane potential collapse during 
apoptosis 
   The mitochondrial permeability transition (MPT) denotes the increase of the permeability of the 
mitochondrial inner membrane that leads to the collapse of ΔΨm, mitochondrial swelling, and 
rupture of the outer mitochondrial membrane (Tsujimoto and Shimizu, 2007). It is generally thought 
that MPT is induced as a result of channel formation (permeability transition pore, PTP) between 
the inner and outer membrane. This channel is thought to consist of the voltage-dependent anion 
channel (VDAC) in the outer membrane, the adenine nucleotide traslocator (ANT) in the inner 
membrane and the cyclophilin D (Cyp D) in the matrix.  
   The role of MPT in apoptosis is controversially discussed. The hypothesis that MPT is involved in 
apoptosis is largely based on findings that inhibitors of Cyp D or ANT, cyclosporine A and 
Bonkrecik acid respectively, can inhibit apoptosis in some experimental models (Custodio et al., 
2001; Zamzami et al., 1996). In addition, MPT may result in the permeability changes of the outer 
mitochondrial membrane leading to the cytochrome c release during apoptosis (Green and Kroemer, 
2004). However, recently it has been demonstrated that cell lines isolated from Cyp D deficient 
mouse undergo apoptosis normally in response to various stimuli, showing that MPT (or at least its 
component Cyp D) is not involved in apoptosis (Nakagawa et al., 2005). In contrast, Cyp D and 
MPT seem to be instrumental in some forms of necrotic cell death (Nakagawa et al., 2005). 
However, the collapse of ΔΨm is frequently seen in apoptosis induced by variety of stimuli. Thus it 
can be speculated that the permeabilization of the inner membrane participates also to apoptotic cell 
death. The ΔΨm collapse leads to cessation of ATP synthesis, release of Ca2+ from the matrix, 
production of reactive oxygen species (Skommer et al., 2007), and these changes may promote both 
apoptotic and nectrotic cell death.  
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Cytochrome c and other pro-apoptotic molecules released from the IMS 
   Cytochrome c is a small heme-containing protein bounded to outer face of the IM and involved in 
the electron transport and oxidative phosphorylation (Garrido et al., 2006). In addition to its vital 
function in the respiratory chain, cytochrome c has distinct function as a regulator of apoptosis. 
Upon apoptotic stimulus, cytochrome c is released through permeabilized mitochondrial outer 
membrane in to the cytosol, where it binds to apoptotic protease-activating factor-1 (Apaf-1) and 
induces ATP dependent formation of protein complex called the apoptosome (Riedl and Salvesen, 
2007). In addition to cyt c, ATP and Apaf-1, cysteine protease caspase-9 is recruited to apoptosome 
where it undergoes dimerization and activation. Caspase-9 functions as an initiator caspase of the 
mitochondrial pathway of apoptosis and further activates the executioner caspases responsible for 
the targeted proteolysis of cellular substrates (see later).  
   Recently, Hao et al. developed a mouse model in which mutated cytochrome c retained normal 
respiratory function but lacked apoptotic function due to failure to oligomerize with Apaf-1 (Hao et 
al., 2005). In these animals, apoptosis during brain- and lymphocyte development was severely 
disrupted showing the importance of cytochrome-c mediated apoptosis in the organogenesis. 
Although the fibroblasts of this cytocrome-c mutated mouse model were resistant to caspase 
activation and apoptosis, the thymocytes were sensitive to apoptosis induced by variety of signals. 
Thus the authors concluded that there may be cytochrome-c / apoptosome independent pathways of 
caspase-activation. Indeed, in addition to cytochrome c, also other proapoptotic molecules are 
released from the IMS during apoptosis. The SMAC/DIABLO and HtrA2/Omi released to the 
cytosol bind and inactivate IAPs (Inhibitor of Apoptosis Proteins) and thus facilitate the activation 
of caspases (Figure 1.) (Suzuki et al., 2001; Verhagen et al., 2000). Apoptosis-inducing factor (AIF) 
is expelled from IMS due to apoptotic stimulus and translocates to nucleus where it contributes to 
DNA fragmentation (Porter and Urbano, 2006). However, AIF is centrally involved in the oxidative 
phosphorylation, and thus it has been speculated that the main mechanism of how AIF release 
triggers cell death is related to failure in energy metabolism (Porter and Urbano, 2006). Endo G was 
previously shown to cause chromatin condensation and DNA fragmentation independently of 
caspase activation. However, the role of EndoG in apoptosis is recently questioned in the basis of 
genetic studies (Irvine et al., 2005). 
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2.1.3 Caspases – executioners of the apoptotic cell death 
   Caspases are cysteine proteases which play an important role in the regulation and execution of 
apoptotic cell death. The term caspase is derived from cysteine dependent, aspartatic acid specific 
protease, which denotes that the cysteine is involved in the catalytic site of the protease which 
cleaves its substrate proteins after the aspartatic acid residue (Boatright and Salvesen, 2003). 
Recognition of at least four amino acids next to the cleavage site is involved for substrate binding 
and cleavage (Thornberry and Lazebnik, 1998). This four amino acid recognition sequence differs 
among the caspases and explains the differences in their action. The activation of caspases does not 
lead to indiscriminate protein digestion, instead highly specific set of target proteins is cleaved 
elegantly resulting in the loss or change in their function.  
    The caspases are synthesized and stored as inactive precursors (zymogens) which became 
activated upon apoptosis induction (Boatright and Salvesen, 2003). The first caspases to be 
activated in the proteolytic cascade are termed initiator caspases (caspases -2, -8, -9 and -10). The 
zymogens of the initiator caspases exists within a cell as inactive monomers, which became 
activated by dimerization at multiprotein activating complexes (Boatright and Salvesen, 2003; 
Boatright et al., 2003; Donepudi et al., 2003). In general, two ways of initiator caspase-activation 
have been described; the extrinsic pathway is initiated by ligation of death receptors belonging to 
TNF-receptor superfamily (TNFR1, Fas/CD95, TRAIL-R1/R2) and the intrinsic pathway is 
triggered by MOMP as a result of stress signals that converge on the level of mitochondria (Figure 
1.).  
 
The death receptor (extrinsic) pathway  
   The extrinsic pathway of apoptosis is triggered by binding of extracellular ligand (TNF, FAS-L, 
TRAIL) to their specific transmembrane receptors (Ashkenazi and Dixit, 1999). However, in the 
case of Fas/CD95 receptor, also ligand independent activation by receptor aggregation has been 
described (Hennino et al., 2001). Upon activation, the death receptors form trimeric complexes 
which bind and recruit the adaptor protein FADD (Fas-associated death domain). FADD in turn 
binds caspase-8 zymogens resulting in the formation of the death inducing signaling complex 
(DISC) (Medema et al., 1997), a multiprotein complex which promotes the dimerization of caspase-
8 leading to its activation (Donepudi et al., 2003). In addition to caspase-8, caspase-10 can be 
recruited to DISC and work as an initiator caspase of the death receptor pathway at least in some 
cell models (Kischkel et al., 2001). 
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   Two types of cells which differ in their involvement of mitochondria in the death receptor 
mediated apoptosis has been described (Scaffidi et al., 1998). In type I cells the amount of caspase-8 
activated at the DISC is sufficient for the activation of the executioner caspases without the 
involvement of mitochondria. In type II cells, small amount of activated caspase-8 cleaves and 
activates Bid, a pro-apoptotic member of the Bcl-2 family, leading to its translocation to 
mitochondria where it induces MOMP and engages the extrinsic pathway with the intrinsic pathway 
of apoptosis (Li et al., 1998) (Figure 1.).  
   Besides functioning as an activation platform for caspase-activation, DISC is also involved in the 
regulation of the initiator caspase activation by recruiting the caspase-8 homolog FLIP (FLICE-like 
inhibitory protein) (Irmler et al., 1997; Scaffidi et al., 1999). FLIP has structural homology with the 
caspase-8 and can thus replace it in the DISC. Generally, FLIP is considered as an apoptosis 
inhibiting molecule as it can displace caspase-8 from the DISC while it does not itself have notable 
proteolytic activity. 
 
The mitochondria-dependent (intrinsic) pathway 
   The intrinsic or mitochondrial pathway of apoptosis is triggered by multiple cellular or 
extracellular stress signals, such as growth factor withdrawal, DNA damage or radiation, which 
converge on the level of mitochondria. The hallmark of the intrinsic pathway is the activation of 
caspase-9 at the multiprotein activating complex called the apoptosome (Riedl and Salvesen, 2007). 
As a result of mitochondrial permeability change, cytochrome c is released into the cytosol, where it 
binds to an intracellular receptor molecule apoptosis-inducing factor-1 (Apaf-1) leading to its 
oligomerization and ATP dependent conformational change. Apaf-1 in turn recruits caspase-9 via its 
N-terminal caspase-activation recruitment domain (CARD). Activation of caspase-9 monomers at 
the apoptosome is achieved by dimerization (Riedl and Salvesen, 2007). Moreover, it has been 
suggested that the apoptosome increases the caspase-9 affinity for procaspase-3 (Yin et al., 2006) 
   Activation of the executioner caspases (caspases -3, -6 and -7) involves their proteolytic 
processing by the initiator caspases (Thornberry and Lazebnik, 1998). The cleavage of the linker 
domain of executioner caspases results in the formation of small and large caspase subunits, which 
heterodimerize to form a catalytical unit. Executioner caspases contribute to apoptosis by cleaving 
structural proteins of the nucleus (lamin), proteins involved in the regulation of cytoskeleton 
(gelsolin, focal adhesion kinase) and proteins involved in the DNA repair (DNA-PKcs) or replication 
(replication factor
 
C) (Thornberry and Lazebnik, 1998). In addition, executioner caspases can 
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enhance mitochondrial dysfunction and hence cell death by cleavage of the respiratory chain 
components (Ricci et al., 2004) or anti-apoptotic Bcl-2 family proteins (Chen et al., 2007; Cheng et 
al., 1997). 
   The activity of executioner caspases is kept in check by Inhibitor of Apoptosis Proteins (IAPs) to 
ensure that these proteases are not activated inappropriately (Verhagen et al., 2001). To date, several 
members of the IAP-family have been characterized, including XIAP, cIAP1, cIAP2 and surviving 
(reviewed in (D'Amelio et al., 2008)) The IAPs in turn can be inactivated by SMAC/DIABLO or 
HtrA2/Omi released from IMS during the apoptotic insult (Figure 1.) (Suzuki et al., 2001; Verhagen 
et al., 2000; Verhagen et al., 2001). 
In addition of their death promoting effect during apoptosis, caspases may also function in the 
regulation of cell survival, proliferation, differentiation and inflammation (Lamkanfi et al., 2007). 
 
2.2. B cells and the humoral immune response 
2.2.1 An overview of the humoral immune response 
   The main function of the immune system is to protect our body from invading infectious agents. 
The adaptive immune response enables the specific destruction of invading micro-organisms such 
as viruses and bacteria, whose foreign structures work as antigens. The immunological memory and 
the adaptation to combat micro-organisms that are transforming all the time are instrumental 
properties of the adaptive immunity. 
   Failures in the immune system are associated with several diseases. Disturbance in the 
development of a specific immune response (immunodeficiency) leads to overwhelming or 
recurrent infections. On the other hand, a normal immune response can be inappropriately directed 
against harmless, non-infectious agents, such as in the case of allergy or autoimmune diseases. 
T and B lymphocytes are greatly in charge for the development of a specific immune response. Each 
individual lymphocyte bears a unique variant of an antigen receptor, so that lymphocytes 
collectively have an enormous repertoire of antigen receptors which can bind highly diverse 
antigens.  
   The humoral immune response is mediated by antibodies (immunoglobulins), which are secreted 
by terminally differentiated B cells called plasma cells. The antibody is a soluble form of the B cell 
surface antigen receptor, and recognizes the same antigen as the receptor. Antibodies secreted to 
circulation delete micro-organisms by three main ways. Antibodies can bind to micro-organisms 
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and thus prevent their adherence to host cell (neutralization). Secondly, antibodies can bind to the 
surface of pathogens and promote its phagosytosis by macrophages and other effector cells 
(opsonization). Thirdly, antibody binding to the surface of micro-organism may trigger the 
activation of complement system leading to pore formation on the target cell surface and cell lysis.  
2.2.2 The B cell antigen receptor; structure and activation 
 
 
Figure 3. The structure of B cell receptor complex 
The surface immunoglobulin consists of two heavy and two light chains combined to each other by 
disulfide bonds. Surface immunoglobulin consists of variable and constant regions which determine 
the antigen binding capacity and effector functions of the immunoglobulin, respectively. Moreover, 
immunoglobulin can be divided on two structural fragments; fragment antigen binding (Fab) and 
fragment crystallizable (Fc). The accessory proteins Igα and Igβ contain the ITAM motifs critically 
involved in the BCR signaling. 
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   The main functions of the BCR are to recognize foreign antigens, to internalize antigens for 
further processing and presentation to T-helper cells, and to transmit activating signals to the cells 
interior. The activating signals initiated after BCR-stimulation have different outcomes depending 
on the maturational stage of a B cell. In mature B cells, BCR triggering leads to proliferation and 
survival, whereas in immature B cells BCR activation may lead to inactivation or apoptosis (Niiro 
and Clark, 2002). The central question in the research concerning the BCR signaling is how the 
signals initiated from the same receptor can evoke these different responses. 
   The B cell receptor complex is made up of the cell surface immunoglobulin combined with 
accessory proteins Igα and Igβ (Figure 3.) (Reth and Wienands, 1997). The immunoglobulin part 
consists of two heavy and two light chains combined to each other by disulfide bonds. The variable 
regions of both light and heavy chains are unique in each B cell clone and responsible for antigen 
binding specificity. Diversity of the antigen binding capacity is a result of immunoglobulin variable 
region gene rearrangements during early B cell development (Busslinger, 2004). The surface 
immunoglobulin has the same antigen specificity as the soluble immunoglobulin that the cell will 
eventually produce as a plasma cell.  
   The surface immunoglobulin has a short cytoplasmic tail and can not transmit signals in to cells 
interior. Accessory proteins Igα and Igβ provide the cytoplasmic domains crucial for BCR signaling 
(Reth and Wienands, 1997). They contain amino acid sequences called immunoreceptor tyrosine-
based activation motifs (ITAMs), which become phosphorylated by Src-family protein tyrosine 
kinases (PTKs), such as Lyn, after engagement of BCR by antigen (Niiro and Clark, 2002). The 
phosphorylated ITAMs in turn recruit and facilitate the activation of protein kinases Syk and Btk, 
which in turn activate the phopholipase Cγ2 (PLC γ2), phosphatidyl-inositol-3-kinase (PI3K) and 
Ras-Raf-1-ERK downstream signaling pathways (Figure 4.) (Niiro and Clark, 2002). Adaptor 
proteins such as B-cell linker (BLNK) and BAM 32 (B-lymphocyte adaptor molecule of 32 kD) 
connect the initial kinases with downstream signaling molecules.  
   The activation of ERK1/2 (extracellular signal regulated kinase) has been associated with both 
proliferation and apoptosis of B cells (Koncz et al., 2002; Lee and Koretzky, 1998). ERK1/2 are 
activated by a cascade of upstream protein kinases Ras and Raf-1 (Niiro and Clark, 2002). In 
addition to Ras-Raf-1, the PLC-γ2 signaling pathway has been shown to participate in the activation 
of ERKs (Hashimoto et al., 1998). In mature B cells, sustained activation of ERK after BCR 
stimulation was associated with the up-regulation CREB and Elk-1, transcription factors involved in 
cell proliferation (Koncz et al., 2002). In line with this, the pharmacological inhibition of ERK 
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activation suppressed BCR-induced proliferation in mature B cells (Richards et al., 2001). In 
contrast, it was shown in the murine immature B cell line that ERK2 plays an active role in anti-
IgM-mediated apoptosis (Lee and Koretzky, 1998). In human B lymphoma cell lines, the Ras-ERK 
pathway activation was connected with up-regulation of Bim and induction of apoptosis (Stang et 
al., 2009). Thus, the role of the Ras-Raf-1-ERK pathway in the regulation of B cell fate may depend 
on the maturational stage of the B cell and the kinetics of ERK activation. 
 
Figure 4. B cell receptor-induced signal-transduction pathways 
Three main pathways are activated after B cell receptor activation; Ras, PLC and PI3-kinase 
pathways. The most important downstream mediators include mitogen activated protein kinases 
(MAPKs), NF-AT, cyclin D and NF-κB.  
 
    
   The PI3K mediates B cell survival by activating downstream kinase AKT which promotes cell 
survival by directly inhibiting pro-apoptotic Bcl-2 family member BAD and by inducing the 
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expression of pro-survival proteins (Bcl- xL, Bcl-2, A1) through activation of NF-κB. In addition, 
AKT inhibits GSK3 (glycogen synthase kinase-3) leading to stabilization of Cyclin D and Myc, 
thereby facilitating cell proliferation (Niiro and Clark, 2002). 
Activated PLCγ cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate 
(IP3) and diacylglyserol (DAG) (Campbell, 1999). IP3 binds to its receptors on endoplasmic 
reticulum leading to the release of intracellular calcium stores, while DAG activates certain 
isoforms of PKC. The release of intracellular Ca
2+
 and PKC activation are crucial for the activation 
of mitogen activated protein kinases (MAPKs), such as ERK, JNK and P38 (Niiro and Clark, 2002). 
In addition, elevated cytosolic Ca
2+
 level triggers the activation of calcineurin, a protein 
phosphatase, which can activate target molecules including caspase-2, transcription factor NFATc2 
or mitogen activated protein kinases (MAPKs) p38 and JNK (Chen et al., 1999; Graves et al., 1996; 
Kondo et al., 2003). The activation of JNK and p38 have been associated with BCR apoptosis in 
B104 cell line (Graves et al., 1996). In addition, JNK and p38 are activated after various stress 
signals, such as radiation induced DNA damage (Chen et al., 1996). 
2.2.3. B cell maturation  
 
The selection of immature and transitional B cells; the negative selection during B cell 
development in the bone marrow and periphery 
   During early B cell development in the bone marrow, the B cell precursors undergo recombination 
of the immunoglobulin heavy (H) and light (L) chain genes which creates diversity to antigen 
binding capacity. The recombination is accomplished by RAG1/2 proteins which rearrange first 
variable (V), diversity (D) and joining (J) regions of the Ig heavy chain followed by VJ regions of 
the light chain (Busslinger, 2004). If the rearrangement is completed successfully, the B cell 
expresses functional surface IgM receptor combined with accessory proteins Igα and Igβ and its 
development can continue. 
   The gene rearrangement process may probably produce B cells with self-reactive receptors which 
have to be eliminated to maintain immune system self-tolerant. The mechanisms of this called 
negative selection include deletion, receptor editing, anergy and inergy (Hartley et al., 1991). 
Deletion of self-reactive immature B cells has been demonstrated in transgenic animal models 
(Hartley et al., 1991; Nemazee and Burki, 1989). Moreover, in vitro, immature B cells die by 
apoptosis after antigen receptor activation, and these cells have been used as a model of negative 
selection (Norvell et al., 1995). Especially, strong signal generated by multivalent antigen drives 
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cells to deletion. However, the bone marrow developing B cells might be rescued by receptor 
editing process, whereby self-reactive antigen receptor is replaced by newly generated non-self-
reactive antigen receptor after recurrent immunoglobulin gene-rearrangement (Melamed and 
Nemazee, 1997). 
   Immature B cells which bind soluble self antigens are not deleted immediately in the bone 
marrow, but instead they migrate to the periphery where they remain permanently unresponsive or 
anergic to further antigenic stimulation (Duty et al., 2008). The anergic B cells die rapidly in the 
periphery mostly because of the lack of survival signals from the antigen specific T cells. The fourth 
potential fate of a self-reactive B cell is that they ignore the antigenic stimulus which is too weak to 
activate antigen receptor. Alternatively, some self-antigens may not be presented in the bone 
marrow, and B cells specific for these self-antigens are left unaffected and enter the periphery. 
Contrary to anergy, ignorance can be later counteracted if the concentration of the soluble antigen 
suddenly increases so that the antigen receptor activation is possible. Thus, ignorant B cells may be 
thought as a “seeds” of the autoimmune diseases. However, normally these low-affinity self reactive 
B cells are not activated because of the lack of proper T cell help. 
   Only the B cells, which are not negatively selected in the bone marrow, have the potential to 
further develop to antibody secreting mature B cells. However, still majority of the cells that enter 
peripheral B cell pool are short lived and die before maturation is completed (Thomas et al., 2006). 
These transitional B cells are dependent on the survival signals which they get at the lymphoid 
follicles of peripheral lymphoid tissues. Continuous expression of B cell receptor seems to be 
instrumental for B cell survival, since gene deletion experiments have shown that B cells lacking the 
functional BCR complex are rapidly eliminated from the peripheral B cell pool (Kraus et al., 2004; 
Torres et al., 1996). It seems that instead of antigen dependent activation of the receptor, antigen 
independent signaling from the BCR is sufficient for survival (Monroe, 2006). In addition, 
maturating B cells of the periphery also need other survival signals for their survival, such has 
BAFF receptor activation by BAFF, a ligand belonging to TNF receptor family (Stadanlick and 
Cancro, 2008).  
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B cell activation by T cells  
   When the maturating B cells first encounter their specific antigen, they have to be activated by 
BCR-stimulation to generate effective immune responses. As in the case of immature B cells, the 
antigenic stimulus leads primarily to deletion process. However, when antigen is delivered with co-
stimulatory signals derived by the activated T cells, the outcome is B cell activation instead of 
deletion. 
Figure 5. Crosstalk between B cell and a helper-T cell 
Two events are necessary for antigen dependent B cell activation. Firstly, antigen binding triggers 
the B cell receptor activation, antigen internalization and antigen presentation as peptides on the 
surface of MHCII molecule. Secondly, B cell receives activating CD40-ligand (CD40-L) and 
cytokines from an antigen specific T cell. Abbreviations: BCR; B cell receptor, TCR; T cell 
receptor, MHCII; major histocompatibility complex II. 
 
   Crosstalk between a B cell and a helper-T cell specific to the same antigen is mandatory for B cell 
activation (Figure 5.). After the first encounter of an antigen, antigen specific T and B cells are 
trapped in border between T-and B-cell zones in the spleen and lymph nodes, where antigen is 
presented in the surface of antigen presenting cells (dendritic cells) (MacLennan et al., 1997). After 
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antigen binding by BCR, the antigen is internalized and presented as peptides on the surface of a B 
cell in MHCII-antigen complex, which is recognized by a T cell specific to the same antigen. 
Subsequently, the T cell delivers contact mediated signals, of which the most important are CD40-
ligand and cytokines (IL4, IL5 and IL-6), to the B cell leading to its activation (Van den Eertwegh 
et al., 1993).  
Affinity maturation in germinal centers 
Figure 6. The germinal center reaction Antigen activated B cell differentiates into centroblasts 
that undergo proliferation and somatic hypermutation (SHM) in the dark zone of the germinal center 
(GC). Centroblasts then move in the light zone of the GC and differentiate into centrocytes which 
have three fates: centrocytes with self-reactive or non-binding antigen receptors are deleted by 
apoptosis, while high affinity centrocytes are selected for further differentiation to memory B cells 
or antibody secreting plasma cells. 
    
After B cell activation, some of the B cells directly differentiate to antibody secreting short lived 
plasma cells, which are responsible for the primary IgM-mediated responses against an antigen. 
This primary response offers the first line defense against the invading agent, but the immune 
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response is further improved by the antibody affinity maturation and isotype switching, which 
ensures that antibodies will have more effective binding capacity and can evoke different effector 
functions. 
   The affinity maturation takes place in germinal centers, which are formed by rapidly proliferating 
B cells termed centroblasts (MacLennan, 1994) (Figure 6.). The vigorous proliferation is associated 
with a somatic hypermutation (SHM), a process which introduces non-random, single base point 
mutations into IgV-gene regions that encode the antigen binding site. Centroblasts then differentiate 
into centrocytes, which are subjected for selection on the basis of their antigen binding capacity 
(Figure 6.). Most of the centrocytes have gained deleterious mutations on their Ig-genes leading to 
expression of a low affinity or a non-functional antigen receptor. These centrocytes are eliminated 
by apoptosis. In addition, the SHM may lead to generation of B cells with self-reactivity, and also 
these cells are eliminated by apoptosis because of the lack of survival signals (CD40-ligand) 
delivered by activated T cells. Only the centrocytes with a high affinity BCR are able to bind 
antigen efficiently and present it to helper T cells and follicular dendritic cells (FDC) to gain the 
appropriate signal for further differentiation to antibody secreting plasma cells or memory B cells. 
Some of the B cells may go repeated rounds of proliferation, SHM and selection to further improve 
the antigen binding capacity. A subset of centrocytes undergoes immunoglobulin glass –switch 
recombination, which results in the production of different immunoglobulin subclasses by plasma 
cells (MacLennan, 1994).  
2.2.4 Life and death decisions of a B cell; regulation of B cell apoptosis 
   To maintain B cell homeostasis, the high generation rate of B cells must be counteracted by 
elimination of deleterious or extraneous B cells. Mainly, these unwanted cells are deleted by 
apoptosis during various check points of B cell maturation process (see B cell maturation). 
Apoptosis plays an important role in the negative selection of bone marrow immature B cells and 
GC B cells. In addition, excess B lymphocytes are eliminated by apoptosis after the antigenic 
challenge. The fate of a B cell is regulated by both survival and death signals originating from 
stromal cells of lymphoid organs and activated T cells. Here, I will focus on the regulation of B cell 
apoptosis during the GC reaction, and the signaling through antigen-, Fas-, and CD40-receptors, the 
main regulators of B cell apoptosis. Knockout models of Fas and CD40 receptors and their 
downstream mediators are developed to study their role in GC B cell development (table 1.). 
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Table 1. Knockout models of receptors and their downstream mediators controlling the 
germinal center reaction.  
The knockout models included are B cell-specific, so that only B cells were deficient of the targeted 
gene. 
Receptor Knockout model Phenotype Publication 
Fas/CD95 Fas  (the 
lymphoproliferation 
mutation) 
Lymphadenopathy, 
accumulation of heavily 
mutated memory B cells 
Takahashi et al., 2001; 
Watanabe-Fukunaga et 
al., 1992 
 Fas  (GC B cell-specific) Fatal lymphoproliferation Hao et al., 2008 
 FADD  Increased splenic and lymph 
node B cells 
Imtiyaz et al., 2006 
CD40 CD40  Defective GC formation and 
class switching 
Kawabe et al., 1994 
 c-FLIP  Reduced numbers of peripheral 
B cells that were sensitive to 
Fas-induced apoptosis 
Zhang et al., 2009 
 NF-κB c-Rel   Defect in B cell proliferation Cheng et al., 2003 
 NF-κB RelA Defective production of IgG 
and IgA antibodies 
Doi et al., 1997 
 
Apoptosis during GC reaction 
   GC centrocytes are especially prone to apoptosis to ensure the rapid elimination of B cells with 
newly generated non-functional or non-binding antigen receptors. Only few of the maturating B 
cells have improved binding capacity for antigen after SHM and the rest of the B cells undergo cell 
death by apoptosis and are removed by macrophages which are found abundantly in the GC. The 
GC B cells are susceptible for both spontaneous and receptor mediated apoptosis, and these 
mechanisms act in concert to ensure effective selection of B cell clones during the GC reaction.  
Isolated GC cells and also their malign counterparts die spontaneously in vitro, if they are not 
rescued by survival signals provided by follicular dendritic cells or T – helper cells (Eray et al., 
2003; Goval et al., 2008; Liu et al., 1989). 
   The death receptor CD95/Fas is one of the major regulators of the GC B cell apoptosis (van Eijk 
et al., 2001). The negative selection of GC B cells was severely disrupted in mice with mutated Fas 
receptor (the lymphoproliferation mutation), resulting in lymphadenopathy and accumulation of 
self-reactive B cells with somatically mutated surface IgG (Takahashi et al., 2001; Watanabe-
Fukunaga et al., 1992). This finding was repeated also in another Fas-deficient mouse model, in 
which non-functional Fas was associated with the accumulation of autoreactive and low-affinity B 
cell clones (Hao et al., 2008). It has been suggested that the GC B cells contain preformed CD95 
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DISC, in which the caspase-8 can be activated spontaneously without the involvement of  the Fas-
ligand (Hennino et al., 2001). In this model, the death receptor activation is inhibited by anti-
apoptotic c-FLIP (cellular FLICE inhibitory protein) which can interfere with caspase-8 in the pre-
formed DISC (Scaffidi et al., 1999). Without survival signals provided by CD40- or antigen 
receptors or tropic factors from stromal cells, c-FLIP is rapidly degraded from the DISC leading to 
caspase-8 activation and apoptosis (Hennino et al., 2001; van Eijk et al., 2001). However, Fas-
ligand expression at the mRNA level has been detected in GC T cells pointing out that the Fas 
receptor activation might also be dependent on Fas ligand expressed on T-cells (Kondo et al., 1997). 
The expression of Fas receptor is negatively correlated with the expression of anti-apoptotic Bcl-2 
protein, since Bcl-2 protein level has been shown to drastically decrease during the GC reaction to 
enhance Fas-mediated apoptosis (Kondo and Yoshino, 2007). 
   There is some controversy concerning the role B cell receptor stimulation in the selection process 
of GC B cells. In the model of GC mediated selection presented above, BCR-mediated signal is 
mainly proposed as a survival signal involved in the positive selection. However, according to 
another hypothesis, signaling through the BCR is involved in the negative selection of somatically 
mutated centrocytes with self-reactivity. This model is supported by findings that isolated BC B 
cells and also their malign counterparts are susceptible for apoptosis induced by BCR triggering 
(Billian et al., 1997; Eray et al., 2003). However, in both of the above mentioned models, activating 
signals from CD4+ T cells (CD40L and IL-4), are critically involved in the positive selection of 
high affinity, self tolerant centrocytes. 
 
CD40-CD40L interactions in the regulation of B cell survival 
   CD40 is a 50 kDa transmembrane protein, which is expressed on B lymphocytes, monocytes and 
dendritic cells and in addition several non-hematological tissues. It is also expressed by malignant 
cells originating from these cells, including B and T cell lymphomas, multiple myeloma and 
Hodgkin`s disease (Dallman et al., 2003). The ligand for CD40 (CD40L, CD154) is a 
transmembrane protein expressed transiently on activated CD4+ T lymphocytes (van Kooten and 
Banchereau, 2000; Younes and Kadin, 2003). In addition, CD40L expression has been documented 
in activated B cells, natural killer cells, monocytes, basofils and dendritic cells. Constitutive 
expression of CD40L has been demonstrated in a variety of B cell malignancies, including follicular 
lymphoma, mantle cell lymphoma, diffuse large cell B cell lymphoma and chronic lymphoid 
leukemia (Younes and Kadin, 2003). 
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   The main function of CD40 is the regulation of T-cell mediated B-cell activation during humoral 
immune response. The CD40 stimulation promotes B cell proliferation, immunoglobulin production 
and class switching, GC formation and establishment of B cell memory (van Kooten and 
Banchereau, 2000; Younes and Kadin, 2003).  
   The importance of CD40-CD40L interactions in the regulation of humoral immunity are 
demonstrated in vivo in a human immunodeficiency disease X-linked hyper IgM syndrome in which 
CD40 signaling is severely impaired due to mutations in the gene encoding CD40L. The disease is 
characterized by accumulation of IgM type antibodies because of impaired Ig class switching, and 
defects in the formation of GC and development of memory B cells (Korthauer et al., 1993). A 
similar phenotype is presented also in CD40L or CD40 deficient mouse models (Dallman et al., 
2003).  
   Several in vitro studies have demonstrated the pivotal role of CD40 in the regulation of GC B cell 
apoptosis. Isolated GC B cells die rapidly in vitro, unless they are not rescued by CD40L expressed 
transiently on activated CD4+ T cells (Hennino et al., 2001). In addition, CD40 can counteract both 
Fas and BCR -mediated apoptosis in both isolated GC B cells and in their malign counterparts 
(Choe et al., 2000; Cleary et al., 1995; Eeva et al., 2003; Eeva et al., 2007). 
CD40 contains a cytoplasmic tail, which can activate several intracellular signaling pathways by 
binding adaptor molecules called TNF receptor associated factors (TRAFs) (van Kooten and 
Banchereau, 2000). The activation of TRAF2 has been suggested as mediator of NF-κB activation 
after CD40 ligation (Rothe et al., 1995). The NF-κB family includes the members p50, p65 (relA) 
and c-Rel (Berberich et al., 1994), which are involved in the transcriptional control of several anti-
apoptotic genes including c-FLIP (Kreuz et al., 2001), survivin (Granziero et al., 2001), Bcl-2 
(Holder et al., 1993), Bcl-xL and Bfl-1 (Lee et al., 1999). NF-κB activation is at least partially 
mediated by a decrease in the half life of IκB-α and IκB-β proteins, which sequester NF-κB in the 
cytosol in an inactive form (Schauer et al., 1996). Besides NF-κB activation, CD40 triggering leads 
to the activation of other signaling pathways, including p38, JNK, ERK, JAK-STAT and NF-AT 
pathways, but their importance in the regulation CD40 mediated survival is currently not well 
characterized (van Kooten and Banchereau, 2000). 
2.2.5 GC as an origin of B cell malignancies 
   The microenvironment that enhance vigorous cell proliferation, the SHM process, and a low 
threshold for acquired mutations makes the GC B cells susceptible to malign transformation. The 
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hallmark of a malign transformation is the unregulated accumulation of single clone cells due to 
overwhelming cell proliferation or inaccurate elimination by apoptosis. GC derived B cell 
malignancies are most often associated with an aberrant Ig gene rearrangement, in which a highly 
expressed Ig gene is joined next to genes that regulate cell growth or apoptosis. For example, 
majority of the follicular lymphoma (FL) cells carry the chromosomal translocation t14:18 that 
positions the Ig gene next to the antiapoptotic Bcl-2 gene leading to decreased apoptosis and 
accumulation of long lived cells (Klein and Dalla-Favera, 2008). In Burkitt lymphoma cells the Myc 
oncogene, involved in the control of cell cycle, is placed under the control of Ig loci leading to 
enhanced cell proliferation (Klein and Dalla-Favera, 2008). Aberrant class switch recombination 
leading to dysregulated expression of Bcl-6 may be the transforming event in the development of 
DLBCL (diffuce large cell B cell lymphoma) (Klein and Dalla-Favera, 2008). Constitutive 
expression of Bcl-6 results in the maintenance of proliferative, DNA-damage tolerant centroblastic 
phenotype with subjects the cell for further genetic abnormalities. 
   The FL cells grow in a follicular pattern, and the same cellular components are found in the FL 
follicles as are present in the normal germinal centers. It has been suggested that also the same 
cellular interactions between FDCs, helper T cells and macrophages occur similarly in normal GC  
B cells and FL cells (Kuppers, 2004). The dependence of FL cells as well as normal GC cells on the 
growth support provided by their microenvironment is supported by the fact that the cells are 
difficult to culture in vitro without survival signals provided by FDCs or CD40 (Eray et al., 2003; 
Goval et al., 2008). Recently, a large scale gene-expression profiling study has demonstrated that 
the clinical behavior of FL is not only determined by properties of tumor cells themselves, but also 
by the molecular features of non-malignant tumor-infiltrating immune cells (Dave et al., 2004). 
Another gene expression study demonstrated that especially the activation of CD4+ T-helper cells 
play an important role in rapidly transforming FL with poor prognosis (Glas et al., 2007). In the 
same study, it was found that the gene-expression profiles from of dendritic cells have an impact on 
the growth properties and clinical behavior in FL. Further studies are needed for the better 
understanding how the microenvironment specifically interacts with tumor cells, since this 
knowledge can be used in the future for the development of new immunological treatment strategies 
against FL. 
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2.3. Monoclonal antibody therapy for cancer treatment 
   In monoclonal antibody (mAb) therapy for cancer, the antibody against a specific tumor antigen is 
given to patients as single therapy or in combination to chemotherapeutics to induce depletion of 
cancer cells. In addition to cancer therapy, mAbs that target pro-inflammatory cytokines and their 
receptors are currently used in the treatment of autoimmune diseases, such as rheumatoid arthritis, 
systemic lupus erythematosus (SLE) and vasculitis (Bayry et al., 2007). The advantage of the mAb 
therapy is the specificity of mAbs against tumor cells without a general toxicity associated with 
conventional chemotherapeutics.  
   The target antigens currently used in the cancer therapy have several different biological 
functions, such as regulation of cell death or proliferation, or conduction of growth promoting 
signals inside the cell. Ideally, the target antigen should be expressed only in tumor cells, or in the 
cell type from which the tumor cells arise. The expression of the antigen should not decrease upon 
repeated mAb treatments, and the antigen should not detach from the cell surface upon antigen 
binding. 
   Since the introduction of the hybridoma technique by Kohler and Milstein in 1975 (Kohler and 
Milstein, 2005), specific mAbs have been available as large amounts needed for the therapy. 
Hybridoma cells are produced by fusing a mouse myeloma cell with an antigen specific mouse B 
cell extracted from a mouse immunized with the desired antigen. The resulting hybridoma cell line 
is immortal and produces large amounts of the specific antibody. The pioneer study of mAb therapy 
was conducted in the beginning of the 1980 century, when Nadler et. al applied intravenous mAb 
against the tumor cell antigen to the lymphoma patient (Nadler et al., 1980). Although this pioneer 
study showed no clinical response, it proofed for the first time that mAbs bind specifically to the 
tumor cell antigen in vivo, and the therapy was not associated with a severe toxicity. In 1982, Levy 
et al used an anti-idiotype antibody, an antibody specific to variable region of the B cell surface 
immunoglobulin, to treat lymphoma patient (Miller et al., 1982). This clinical study showed that 
mAb therapy can be directed specifically to lymphoma cells, since all lymphoma cells arise from a 
single transformed cell and thus have uniform immunoglobulin variable regions (idiotype). The 
lymphoma patient treated with anti-idiotype Ab had a complete response to the therapy showing the 
curative potential of the treatment.  
   The first clinical studies of antibody therapy were conducted by using mouse antibodies, which 
appeared to have several shortages in the clinical settings. The mouse antibodies are highly 
immunogenic and thus induce the production of human-antimouse antibodies (HAMAs) as a result 
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of repeated dosing to the patients (Frodin et al., 1992). The mouse antibodies were associated with 
mild adverse effects and the production of HAMAs resulted in too rapid clearance of the mAbs 
from the circulation after their administration (Dillman et al., 1986). Later, the problems associated 
with mouse antibodies were circumvented by the development of human-mouse chimeric antibodies 
in which the Fab part of the immunoglobulin is mouse-derived and the Fc part of the antibody is 
human specific (Figure 7.). More lately, the development of gene technology has enabled the 
development of humanized monoclonal antibodies, in which only the six antigen binding 
polypeptide loops (complementary determining regions (CDRs) are of non-human origin. For 
example, the anti-CD52 antibody alemtuzumab, used for the treatment of chronic lymphocytic 
leukemia, is produced by inserting mouse derived CDRs specific for CD52 into antibody 
“framework” containing heavy and light chains of human origin (Crowe et al., 1992). Subsequently, 
the humanized antibody, containing only CDRs of non-human origin, is expressed on immortalized 
mouse cell line. 
   More recently, new technologies using phage display or transgenic mouse have emerged for the 
generation of fully humanized antibodies (Lonberg, 2008).  To date, two fully humanized 
antibodies, adalimumab and panitumumab, are in the clinical use, and several antibodies in the 
clinical trials. The anti-TNFα antibody adalimumab, used for the treatment of rheumatoid arthritis, 
is produced by phage display technology. The antibody against epidermal growth factor receptor 
(EGFR), panitumumab, is produced using “humanized” transgenic mice, which are able to produce 
human immunoglobulin heavy and light chains after immunization. The antibody producing B cell 
clone specific for EGFR is extracted from the transgenic mouse, and immortalized using Chinese 
ovarian cell line. 
   The humanized and chimeric antibodies contain a human specific Fc part which can activate 
leukocytes and complement system when applied to the human body. Indeed, antigen-dependent 
cellular cytotoxicity (ADCC) and complement mediated cytotoxicity (CDC) are centrally involved 
in the mAb-mediated tumor cell clearance in addition to the direct antigen specific growth-
inhibiting or apoptosis-inducing effect (Villamor et al., 2003) (Figure 8.). ADCC is mediated by 
nonspecific cytotoxic cells such as NK cells, monocytes and macrophages which can recognize the 
Fc part of a tumor-bound antibody by their Fcγ-receptors. The activation of Fcγ-receptors receptor 
induces the secretion of lytic enzymes by the cytotoxic cells which results in the target cell lysis. 
Complement dependent cytotoxicity is induced when antigen-antibody complex deposited on the 
cell surface triggers the activation of classical complement pathway resulting in the formation of 
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large pores on the membrane of the target cell and cell lysis. In addition, ADCC and CDC can act 
synergistically, so that the complement components deposited on the tumor cell surface facilitates 
tumor cell clearance by recruiting phagocytic cells (complement dependent cellular cytotoxity, 
CDCC). 
To further improve immunotherapy, mAbs can be conjugated with toxins, chemotherapeutics and 
radioisotopes, so that the resulting conjugated antibodies carry these cytotoxic agents specifically to 
the tumor cells (Zinzani et al., 2008). 
   In the year 2009, six unconjugated humanized or chimeric monoclonal antibodies, along with one 
radioisotope-conjugated antibody are approved for the clinical treatment of cancer in Finland (Table 
2.). The success of currently used therapeutic antibodies has encouraged scientists to the search of 
novel target antigens suitable for mAb therapy. Currently, several clinical trials are ongoing which 
study the clinical effectiveness of novel mAbs.  
Table 2. Therapeutic monoclonal antibodies approved for use in cancer therapy in Finland. 
The antibodies listed below are used in the treatment of cancer according to Pharmaca Fennica 
2009. In addition, there are several monoclonal antibodies used in the treatment of autoimmunity 
diseases, including rheumatoid arthritis and crohn`s disease, which are not included in the table. 
Abbreviations: EGFR; epidermal growth factor receptor, VEGF; vascular endothelial growth factor 
 Target Indication Reference 
Unconjugated antibodies 
Trastuzumab Her2/neu Breast cancer Guarneri et al., 2008 
Rituximab CD20 Lymphoma Marcus and Hagenbeek, 2007 
Cetuximab EGFR Colorectal cancer Raoul et al., 2009 
Panitumumab EGFR Colorectal cancer Hecht et al., 2007 
Bevacizumab VEGF Colorectal-, lung-, 
kidney- and breast 
cancer 
Tol et al., 2009 
Alemtuzumab CD52 Chronic 
lymphocytic 
leukemia 
Schweighofer et al., 2009 
Immunoconjugates 
Ibritumoab tiuxetan 
(Yttrium-90 conjugated) 
CD20 Lymphoma Zinzani et al., 2008 
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2.4. Follicular lymphoma 
   Lymphoma is a cancer that originates from the lymphocytes of the immune system and presents as 
a solid tumor of lymphoid cells. Traditionally, lymphomas are divided in two groups; hodgkin 
lymphoma which was the first form of lymphoma ever described, and non-hodgkin lymphomas 
(NHLs). More recently, lymphomas are grouped according to WHO classification that recognizes 
over 40 different lymphoma types (Swerdlow et al., 2008). 
2.4.1. Incidence and clinical characteristics 
   Non-Hodgin lymphomas (NHLs) represent a heterogeneous group of malignancies originating 
mainly from B and T lymphocytes of the immune system. Follicular lymphoma (FL) is the second 
most common NHL-subtype comprising 20% of the cases (Anderson et al., 1998). For yet unknown 
reasons, the incidence of FL:s is increasing steadily (Chiu and Weisenburger, 2003). In Finland, 
about 250 new cases of follicular lymphoma are diagnosed annually (Jyrkkiö et al., 2007). 
   The clinical course of FL is extremely variable. In some patients the disease proceed in an 
indolent way over a period of many years whereas in other patients the disease transforms to diffuse 
large cell B cell (DLBC) lymphoma with an aggressive course (Advani et al., 2004). 
   Patients with follicular lymphoma usually presents with an enlarged superficial lymph node. 
Delays in diagnosis are not uncommon, since enlarged lymph nodes may be unnoticed for a 
prolonged period of time. In some patients, lymph nodes grow in deep areas in the retroperitoneal, 
iliac- or mesenteric regions. In those cases, patients may have atypical symptoms and tumor bulk 
may be large at the time of diagnosis. Few patients have symptoms such as fatigue, weight loss and 
night sweating at the time of diagnosis. The bone marrow is affected in about half of the cases. 
Rarely, FL presents as extranodal tumor growth. (Salles, 2007) 
2.4.2 Pathophysiology 
   FL originates from germinal center (GC) B cells of lymphoid tissue. GCs are the sites for antibody 
affinity maturation, a process which enables the development effective immune response (Allen et 
al., 2007). GC:s consist of rapidly dividing centroblasts undergoing somatic hypermutation and 
centrocytes undergoing antigenic selection. Only the centrocytes with improved antigen binding 
capacity escape from the selection and the rest of the centrocytes die by apoptosis. FL is thought to 
arise from accumulation of inappropriately rescued long lived B cells due to resistance in apoptosis. 
Classically, FL cells express anti-apoptotic Bcl-2 protein due to t14;18 translocation which places 
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the bcl-2 gene under the influence of the IgG gene enhancer (de Jong, 2005). However, the t14;18 
translocation is not sufficient alone for lymphomagenesis but it enables the accumulation of 
subsequent genetic lesions affecting proto-oncogenes and tumor-suppressor genes (Schwaenen et 
al., 2009). Recently, gene expression studies have shown that tumor-infiltrating non-malignant 
immune cells may influence the transformation risk and survival of FL patients (Dave et al., 2004). 
   The diagnosis of FL is based on the morphology and immunohistochemistry of an affected lymph 
node. FL cells express the surface markers sIg (M, D, G, A), CD19, CD20, CD22 and CD79a which 
can be detected by immunohistochemistry or by flow cytometry. In addition, germinal center B cell 
antigens CD10 and Bcl-6 are expressed in FL cells (Marcus and Hagenbeek, 2007). 
2.4.3 Current treatment of follicular lymphoma 
   The treatment and prognosis of FL has changed radically during the past years since the 
introduction of monoclonal antibody therapies and stem cell transplantation. The standard 
chemotherapies used at 1980-90s had no effect on overall survival rates and thus advanced stage FL 
has been assumed as incurable disease. However, during the last years, the new therapies directed 
against FL have markedly improved the life expectancy of FL patients. 
   The method of treatment is chosen on the basis of dissemination of a disease at the time of 
diagnosis, which is stated by Ann Arbor classification (Table 3.) (Bendandi, 2008). In addition, the 
age, symptoms and additional diseases of the patient contribute markedly to disease management. 
The prognosis of FL is classified according to Follicular Lymphoma International Prognostic Index 
(FLIPI) (Solal-Celigny et al., 2004) (Table 4.). 
Table 3. The Ann Arbor classification 
Stage Definition 
I The cancer is located in a single region, usually one affected lymph node or one 
extralymphatic organ 
II Two or more affected lymph node regions, or local extralymphatic extension with lymph 
nodes on the same side of the diaphgram 
III Lymph node regions on both sides of the diaphgram, either alone or with local 
extralymphatic extension 
IV Diffuse  involvement of one or more extralymphatic organs, including  involvement of the 
liver, bone marrow, or nodular involvement of the lungs 
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Table 4. Follicular lymphoma prognostic index (FLIPI) 
Feature Good prognosis Adverse prognosis 
Age ≤ 60 years > 60 years 
Serum LDH level normal above normal 
Ann Arbor stage I to II III to IV 
Nodal sites involved ≤ 4 > 4 
Hemoglobin level ≥ 120 g/l < 120 g/l 
 
   At most 20% of the patients have a regional disease without overall symptoms (Ann Arbor I-II) at 
the time of diagnosis. In these cases radiotherapy of an affected lymph node is the most used 
treatment modality. Radiotherapy can cure about half of the patients with stage I disease and quarter 
of the patients with grade II FL (Wilder et al., 2001).  
   The majority of the patients have an advanced stage FL (Ann Arbor III-IV) at the time of 
diagnosis. These patients are treated when disease related symptoms arise, FLIPI score is high or the 
disease is morphologically aggressive (grade 3 which contains over 15 centroblasts per high-power 
field) (Jyrkkiö et al., 2007). Elderly patients or patients with indolent disease and no symptoms 
should first be managed by an active watch-and –wait approach because life expectancy of these 
patients can not be improved by treatment (Ardeshna et al., 2003). Although a wide variety of 
standard chemotherapeutics as single or combination regimen, with or without radiotherapy, have 
been tested against FL, these treatment modalities have no effect on overall survival rates (Ardeshna 
et al., 2003). However, at the last decade, the introduction of a monoclonal anti-CD20 antibody 
rituximab has radically changed the treatment of B cell malignancies. Several large scale 
randomized trials have proved that addition of rituximab to the standard chemotherapy significantly 
improved clinical outcome (progression free survival and overall survival) in patients with 
previously untreated advanced FL (Hiddemann et al., 2007). In addition, the use of rituximab as 
maintenance therapy in relapsed FL responding to chemotherapy or immunotherapy has improved 
progression free survival and overall survival rates (Marcus and Hagenbeek, 2007). The use of 
rituximab maintenance therapy after first line therapy is currently being evaluated. 
   The rituximab therapy is usually well tolerated as compared to the standard chemotherapy which 
is associated with considerable short and long term toxicity. Mild to moderate adverse effects, such 
as hypotension, nausea and general weakness are relatively rarely reported after first infusion 
(Kimby, 2005). Rituximab induces a rapid depletion of CD20 positive peripheral B cells, and the B 
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cell count remains low for the next 6 months (Kimby, 2005). Serum immunoglobulin levels remains 
fairly stable, although a small reduction in serum IgM has been described during prolonged therapy. 
Rituximab therapy has not associated with an increased risk to opportunist infections (Kimby, 
2005), but further studies are needed to evaluate immunological adverse effects associated with the 
long term use of rituximab.  
   In the future, the combination of anti-CD20 antibody with therapeutic radioisotopes may further 
improve the survival of FL patients. Phase II study has demonstrated that 90-Ytrium-ibritumoab 
(tiuxetan) either alone or as consolidation therapy followed by first line therapy improved response 
rates in FL (Zinzani et al., 2008). Further studies are ongoing to establish the use of radiolabeled 
anti-CD20 antibodies in FL treatment. 
   Myeloablative therapy followed by autologous stem cell transplantation (ASCT) and to a lesser 
extend allogenic transplantation had improved long-term outcome of some patients with FL 
(Hiddemann et al., 2007). These approaches are used not so commonly because of treatment related 
toxicity and the risk of secondary malignancy, but may be considered in young patients with 
relapsed FL with poor prognosis. 
 
Rituximab- mechanism of action 
   Rituximab is a chimeric mouse/human monoclonal antibody targeted against human B cell surface 
antigen CD20 (Figure 7.) (Reff et al., 1994). Several characteristics of rituximab make it excellent 
tool for anticancer therapy. The expression pattern of CD20 on B cells is ideal, since it is expressed 
on over 95% of B cell lymphomas (Mathas et al., 2000) and on normal B cells from the pre-B-cell 
stage until the plasma cell differentiation (Reff et al., 1994). Thus, hematopoietic stem cells are left 
unaffected by rituximab that enables the recovery of B cell pool after the therapy. In addition, 
antibody secreting plasma cells do not express CD20, and thus the levels of antibodies are 
maintained during the therapy. The humanized Fc part of the chimeric antibody enables the host 
effector mechanism, which are important in rituximab induced cytotoxicity (see later). The 
production of anti-chimeric antibodies is rare and not of clinical importance as compared to the 
infusion of mouse mAbs which were associated with significant production of anti-mouse 
antibodies (Kimby, 2005). Finally, the CD20 antigen is not internalized from the B cell surface 
upon antibody binding (Reff et al., 1994). 
   Although the clinical results with rituximab have been promising, the exact mechanism how it 
depletes B cells is controversial. Based on in vitro studies, rituximab can induce antibody-dependent 
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cell-mediated cytotoxicity (ADCC) (Reff et al., 1994), complement mediated cytotoxicity (CDC) 
(Harjunpaa et al., 2000; Reff et al., 1994) and apoptosis (Mathas et al., 2000; Shan et al., 2000) 
(Figure 8.). The relative contribution of these mechanisms to B cell depletion in vivo is not known, 
and it is probable that synergistic action of these mechanisms is involved (Flieger et al., 2000). In 
addition to direct induction of apoptosis, rituximab has been shown to sensitize lymphoma cells to 
apoptosis induced by chemotherapeutics such as paclitaxel, fludarabine and cisplatin (Alas et al., 
2000; Alas et al., 2002; Jazirehi et al., 2003).  
 
 
Figure 7. The structure of the rituximab antibody.  
The light- and heavy-chain variable regions are cloned from murine mAb 2B8 that specifically 
recognizes CD20 molecule. The mouse derived genes encoding variable regions are linked with 
genes encoding IgG1 heavy chain and kappa-light chain constant regions of human origin. After the 
fusion of gene segments, the recombinant fusion antibody is produced in Chinese hamster ovarian 
cells. (Reff et al., 1994). Abbreviations: FcγR; Fcγ-receptor 
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Figure 8. Mechanisms of rituximab action 
The proposed mechanisms of action of rituximab include complement-mediated cytotoxicity, 
antibody-dependent cell-mediated cytotoxicity and apoptosis. Abbreviations: B; B cell, FcγR; Fcγ-
receptor, MAC; membrane attack complex, NK; natural killer cell. 
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3. AIMS OF THE STUDY 
 
In general, the aim of the study was to examine the regulation of lymphoma cell apoptosis and 
survival by cell surface receptors. The detailed knowledge of the apoptotic signaling pathways can 
be used as an advantage in the development of new treatment modalities against B cell 
malignancies. 
 
Detailed aims were 
 
1. to study the receptor-mediated regulation of B cell apoptosis during GC negative selection (I). To 
get insight in the molecular mechanisms of B cell receptor – mediated apoptosis (I,III). 
 
2. to study the molecular mechanisms of CD95/Fas –induced apoptosis (II, III). Could death 
receptors serve as potential targets for cancer therapy? 
 
3. to study the signaling pathways involved in the CD40-mediated protection against apoptosis (I, 
II). Could CD40-CD40L interactions between lymphoma cells and the cells in their GC 
microenvironment be responsible for resistance against cancer therapy? How the resistance 
generated by anti-apoptotic function of CD40 can be counteracted? 
 
4. to study the apoptotic signaling pathways induced by rituximab, and explore the means how 
rituximab-induced cytotoxicity can be further enhanced (IV) 
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4. MATERIALS AND METHODS 
4.1. Cell line and culturing 
   The studies presented in the original publications I-IV were performed in a human follicular 
lymphoma (FL) cell line HF1A3. The cell line has been established from an enlarged lymph node of 
a FL patient as described previously (Eray et al., 1994). The original patient sample from which the 
cell line was established contained a nodular and diffuse centroblastic lymphoma according Kiel 
classification (Eray et al., 2003). As a hallmark of a follicular lymphoma, HF1A3 cells contain the 
t(14;18) translocation and overexpress the Bcl-2 protein. Based on the analysis of surface antigens 
and responses against various physiological stimuli, the HF1A3 cells resemble germinal center 
centrocytes undergoing negative selection. The cells were cultured as described in the original 
publications I-IV. 
4.2. Establishment of overexpressing cell lines 
    Transduction refers to the process where foreign DNA is introduced into cell by using a viral 
vector. Commonly, the transduced gene coding for the particular protein is placed under the control 
of a promoter that facilitates the transcription of the gene. In the publications III and IV, we used 
transduced HF1A3 cell lines which overexpressed c-FLIP, Bcl-xL or dominat negative (DN) -
caspase-9 to study the signaling pathways essential for apoptosis.  Transduction was performed by 
using bicistronic lentivirus vector construct containing a gene of interest (DN-caspase-9, Bcl- xL, 
FLIP-short or c-FLIP-long) followed by IRES (internal ribosomal entry site) and the GFP reporter 
gene. Thus, the transduced cells always co-expressed the GFP reporter gene and the gene of interest.  
After the transduction, the GFP-positive cells overexpressing the desired protein were sorted by 
flow cytometry. Cells transduced with GFP reporter gene only were used as control cell line to 
ensure that the cell transduction procedure in itself did not affect the viability of the cells, or made 
them respond differently to apoptotic stimuli. 
   The establishment of DN-caspase-9 and Bcl-xL overexpressing cells has been described in detail 
previously (Nuutinen et al., 2008). The establishment of c-FLIPlong/short overexpressing cells has 
been described in the publication IV. Thus, only short overview of the cell transduction procedure is 
given here. 
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   Firstly, complementary DNA (cDNA) was synthesized by using the total mRNA extracted from 
HF1A3 cells as a template. Thereafter, the sequences for caspase-9, Bcl-xL and c-FLIPshort / long  were 
amplificated  by PCR using cDNA as template. Primer sequences for amplification contained SwaI-
sites which were designed to 5’ ends of the primers. 
   Dominant negative caspase-9 was generated by introducing a point mutation to catalytic cysteine, 
Cys287Ser (TGT→AGT) by site-directed mutagenesis. This method uses oligonucleotide  primer 
containing the desired point mutation, and PCR to introduce the desired mutation to the gene of 
interest. 
   The PCR fragments were isolated from agarose gel and inserted into a plasmid vector (pcr2.1-
TOPO-TA vector, Invitrogen, Carlsbad, CA). Subsequently, competent One Shot TOP10-E.coli 
(Invitrogen) was transformed with the plasmid vector. Thereafter, the sequences were analysed to 
avoid unwanted mutations. After sequencing inserts were cloned to SwaI site of the pWPI-IRES-
GFP (Tronolab, Switzerland) lentivirus-vector. In addition, pWPI-IRES-GFP lentivirus-vector was 
produced and used for the establishment of control cell line. Subsequently, lentiviruses containing 
the vector were produced following the protocol described earlier (Pellinen et al., 2004). 
      The HF1A3 cells were transduced with lentiviral vectors containing DN-caspase-9-IRES-GFP, 
Bcl-xL-IRES-GFP, c-FLIPlong.-IRES-GFP and c-FLIPshort.-IRES-GFP. After three days, cells were 
collected and cultured in fresh medium. The cultures were expanded and GFP positive cells were 
enriched by using flow cytometer until over 95% of the cells were GFP positive. Overexpression of 
Bcl-xL, DN-caspase-9, c-FLIPshort and c-FLIPlong was confirmed by Western blot. 
4.3. Cell treatment experiments 
   In cell treatment experiments, apoptosis was induced by culturing cells in the presence of 
antibodies directed against surface receptors. Physiologically, these receptors are activated by 
binding of endogenous ligands that result in the clustering of adjacent receptors and activation of 
intracellular signaling cascades. Similarly, antibodies used in the experiments cross-link adjacent 
receptors resulting in their activation. The stimulating antibodies used in original publications are 
introduced in table 5. Chemical inhibitors of signaling proteins were used to study importance of a 
particular signaling pathway in apoptosis or survival. The inhibitors used are listed in the table 6. 
The treatment of cells during the experiments is described in detail in the original publications. 
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Table 5. Antibodies used in cell treatment experiments. Abbreviations: κ; kappa, mAb; 
monoclonal antibody, F(ab`)2; fragment antigen binding. 
 
Antibody  Type Antigen Publication 
Anti-κ (anti-IgG) mAb, IgG1 κ-chain constant region of 
human IgG 
I, III 
Anti-Fas (CH11) mAb, IgM Fas/ CD95 II, III, IV 
AF.1.15 mAb, IgG4 CD40 I, II, IV 
Rituximab chimeric, IgG1 CD20 IV 
Anti-human 
IgG(γ)  
F(ab`)2  heavy chain constant region of 
human IgG 
IV 
 
Table 6. Chemical inhibitors of signaling proteins   
Inhibitor Target  Publication 
LY294002 phospahtidyl-inositol-3-kinase (PI3K) I 
PD98059 mitogen-activated protein kinase kinase 1 (MEK1) I 
Gö6850 protein kinase C (PKC) I 
ZM336372 Raf I 
PDTC NF- B II 
z-IETD-fmk caspase-8 II 
z-DEVD-fmk caspase-3 II, III 
z-VAD-fmk caspases III, IV 
  
4.4 Apoptosis detection 
4.4.1 Quantification of fractional DNA content (I-IV) 
   Typical for apoptosis is the activation of endonucleases which cleave nuclear DNA at sites 
between nucleosomes creating internucleosomal DNA fragments of about 200 base pairs and its 
multiples. When DNA from apoptotic cells is analyzed by agarose gel electrophoresis, typical 
“ladder” pattern of about 200 base pairs is detected.  In the publications I-IV, flow cytometry and 
the cell cycle analysis was used for the detection of cells with fragmented DNA. Before the 
analysis, cells were fixed with ethanol and stained with a DNA binding dye propidium iodide. 
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As a result of DNA fragmentation, the amount of cells containing normal diploid chromosomal 
content of DNA decreases, and a population of cells with decreased (hypodiploid) DNA content is 
formed. The proportion of hypodiploid cells (sub-G1 fraction) can be quantified by flow cytometry.  
4.4.2 Mitochondrial membrane potential depolarization (I-IV) 
   Mitochondrial membrane potential depolarization occurs as a result of changes in the 
permeability of mitochondrial membranes during apoptosis. The depolarization can be analyzed 
indirectly by using lipophilic cations which accumulate in the mitochondrial matrix driven by the 
electrochemical gradient between the matrix and the intermembrane space. In publications II-IV, 
loss of mitochondrial membrane potential ( Ψm) was assessed by using a cationic dye tetramethyl 
rhodamine (TMRM, Molecular Probes) as previously described (Castedo et al., 2002). Cells lose 
their capacity to retain TMRM stain when the electrochemical gradient between the matrix and 
intermembrane space is collapsed. In the publication I, loss of mitochondrial membrane potential 
( Ψm) was assessed by ApoAlert Mitochondrial Membrane Sensor Kit (Clontech Laboratories, Inc., 
California, USA). The kit contains a cationic dye MitoSensor
TM
 that fluoresces differently in 
apoptotic and nonapoptotic cells, because of changes in mitochondrial membrane potential. After 
staining, the cells were analyzed by flow cytometry. Only the early apoptotic cells with normal side-
and forward-scatter properties were included in the analysis.  
4.4.3 Cytochrome c release (I-IV) 
   The analysis of cytochrome c release was based on the cell fractionation, which enabled the 
separation of cell fraction containing mitochondria from the cytosol. The cell fractionation 
procedure is described in detail in the publication I. After the fractionation, the amount of 
cytochrome c in both mitochondrial and cytosolic fractions was detected by Western blotting. 
Membranes were reprobed with an antibody against a mitochondrial protein cytochrome oxidase 
subunit IV (COX-4) to ensure that the fractionation procedure was successful and mitochondrial 
fractions contained equal amount of protein. Equal loading of cytosolic samples was assessed by 
immunoblotting with polyclonal anti-actin antibodies.  
4.4.4 Caspase activation (I-IV) 
  Commonly, more than one approach was used for the assay of caspase activity in original 
publications. The activation of DEVD-specific caspases (i.e. caspase-3 and -7) was assessed by 
  
51 
employing fluorochrome substrate Ac-DEVD-AMC (Calbiochem, Ca, USA) which become 
fluorescent upon cleavage by the caspase (publications I, II and IV). In addition to direct analysis of 
caspase activity, activation of DEVD-specific caspases was assessed indirectly by testing whether 
their specific inhibitor z-DEVD-fmk inhibited apoptosis (publications II and III). More specifically, 
activation of caspase-3 was assayed by immunoblotting (publications II, III and IV). Upon 
activation, full length caspase-3 is cleaved, and caspase activation can thus be detected by using an 
antibody which recognizes both the cleavage product and the full length caspase-3. 
   The activation of caspase-8 was assayed indirectly by testing whether a chemical inhibitor z-
IETD-fmk, a specific inhibitor of caspase-8, inhibits apoptotic events (publication II). In addition, 
cell lines expressing c-FLIP proteins, natural inhibitors of caspase-8 activation at the DISC, was 
used to study the role of caspase-8 activation in apoptosis (publication III, IV). The activation of 
caspase-8 was also assayed directly by immunoblotting as an increase of a cleavage product of 
caspase-8 and a decrease of full length caspase-8. Recently, this method has been questioned since it 
has been shown that merely dimerization, and not cleavage of caspase-8, is actually involved in its 
activation (Pop et al., 2007). However, when caspase-8 activation was assessed in our experimental 
model, we get similar results with immunoblotting and by inhibiting caspase-8 activation 
chemically or by c-FLIP overexpression  
   The activation of caspase-9 was assayed by using cells stably overexpressing DN-caspase-9, in 
which caspase-9 activity was blocked by single amino acid mutation at the catalytic site of the 
protease (publications III, IV). 
4.4.5 Cell membrane permeabilization III 
   During both necrotic and the late stages of apoptotic cell death, the cell membrane integrity is lost 
and thus the cells can uptake stains such as propidium iodide, which can be detected by flow 
cytometry. In the publication III, cell permeability assay was used as a cell viability analysis to 
complement other assays of cell death. After staining with propidium iodide, cells were analyzed 
with flow cytometry. The data were expressed as the proportion of living cells (the PI negative cells 
with normal FCS properties) against the total cell count. 
4.5. Western blotting  
   The samples containing equal amount of protein were run on SDS PAGE under reducing 
conditions and transferred to nitrocellulose membranes. The membranes were pretreated with 3% 
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BSA buffer to reduce non-specific binding of antibodies. Following primary antibodies were used 
for the immunoblotting: rabbit polyclonal anti-FLIPshort/long, rabbit polyclonal anti-caspase-3 H-277 
and rabbit polyclonal anti-caspase-8 p20 (Santa Cruz Biotechnology, CA). Horseradish peroxidase-
conjugated goat anti-rabbit (Zymed Laboratories, CA) was used as a secondary antibody. ECL 
chemiluminescence system (Amersham, Arlington Heights, IL) was used for detection.  
4.6. Reverse transcriptional (RT)-polymerase chain reaction 
   In the publication II, C-FLIP mRNA expression was determined by quantitative reverse 
transcription-polymerase chain reaction (RT-PCR). Total RNA extraction and PCR reaction were 
performed as described in the publication II. The PCR products were analyzed on 2% agarose gel 
and visualized by ethidium bromide staining. 
4.7 Statistical analyses 
   In the publications I-II, student’s t-test was used to determine the statistical significance between 
the selected groups. In the publication III, data were analyzed by repeated-measures 
two-way ANOVA and Bonferroni post test. In the publication IV, Oneway ANOVA and Dunnett`s 
post test was used for comparing selected group with other groups. Statistical analyses were 
performed using GraphPad Prism version 4.0 for windows. p < 0.05 was considered significant. 
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5. RESULTS 
5.1. The molecular mechanisms of B cell receptor-induced apoptosis (I, III) 
   The B cell receptor signaling has been a target of enthusiastic research during the past decades as 
there are almost three thousand original articles published that concern BCR signaling. The BCR 
has gained a lot of research interest because of its multiple and important functions in the B cell 
development and adative immunity. As discussed earlier, the response to BCR-stimulation can be 
proliferation, anergy or apoptosis depending on the maturational stage of a B cell and nature of 
antigen binding (Niiro and Clark, 2002). This work studied the molecular mechanisms of BCR-
mediated apoptosis and how signals from the BCR regulate the fate of a germinal center B cell 
coordinately with CD40 and Fas receptors. 
5.1.1 The signal transduction pathways connected with B cell receptor-induced apoptosis 
 
   The signal transduction pathways involved in BCR-induced apoptosis are not yet clarified. Of the 
major signaling pathways activated by BCR, the Ras-Raf-1-ERK and PLC-γ2 activation pathways 
has been connected with apoptosis in some experimental models (Lee and Koretzky, 1998; Stang et 
al., 2009) (Figure 9.). We used the specific inhibitors of Raf, ERK, PKC and p38 to study the 
involvement of these kinases in BCR induced apoptosis (Figure 9.).  
   The Ras-Raf-1-ERK pathway was activated by BCR stimulation in HF1A3 cells, since we could 
demonstrate a transient phosphorylation of ERK1/2 after BCR triggering analyzed by Western blot 
(not shown). However, the selective inhibitors of Raf (ZM 336372) or ERK (PD 98059), showed 
only slight reduction in the percentage of apoptotic cells after BCR triggering (Figure 10.). Pre-
treatment of cells with specific inhibitors of PKC (GÖ 6850) and p38 (SB 203580) showed only 
minor effect on BCR-induced apoptosis (Figure 10.). Based on these results, we could not ascertain 
the signal transduction pathway crucial for BCR-mediated apoptosis in HF1A3 cells. 
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Figure 9. The signal transduction pathways associated with B cell receptor-induced apoptosis.  
The specific inhibitors for the activation of Raf (ZM), PKC (GÖ), P38 (SB) and PI3K (LY) are 
included in the picture. 
5.1.2 The role of caspase-9 and mitochondrion in B cell receptor-induced apoptosis (I, III) 
   To get insight on the mechanism involved in BCR-induced apoptosis, we performed a careful 
kinetic analysis of four sequential molecular events of apoptosis: activation of caspase-3, 
fragmentation of nuclear DNA collapse of ΔΨm and release of cytochrome c (I). The activation of 
caspase-3 was analyzed by a DEVD-specific protease assay and by Western blot analysis of the 
caspase-3 cleavage product. The activation of caspase-3 started to increase 12 hours after BCR 
triggering. Fragmentation of DNA, collapse of ΔΨm and release of cytochrome c followed similar 
kinetics. BCR-induced apoptosis was dependent on the synthesis of new proteins, since the BCR-
induced DNA fragmentation and ΔΨm collapse were abrogated in the presence of the protein 
synthesis inhibitor cycloheximide. 
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Figure 10. The inhibitors of the signaling pathways connected with BCR show no effect on 
apoptosis. HF1A3 cells were cultured in media containing ERK inhibitor PD 98059 (15 μM), Raf 
inhibitor ZM 336372 (10 μM), PKC inhibitor GÖ 6850 (500nM) or p38 inhibitor SB 203580 (10 
μM) for one hour followed by stimulation with anti-IgG antibodies for additional 23 hours. 
Subsequently, cells were harvested for propidium iodide staining followed by analysis of cells with 
fragmented DNA by flow cytometry. The data are presented as mean + SD from three experiments. 
The data are previously unpublished. 
 
   It is well established that caspase-9 is the apical caspase in the intrinsic pathway of apoptosis. To 
explore whether caspase-9 is involved in the BCR-mediated apoptosis, we generated a DN-caspase-
9 overexpressing cell line in which caspase-9 was inactivated by a single amino acid mutation at the 
catalytic domain of the protease (III). The cells transduced with the empty IRES-GFP-vector were 
used as a vector control cells. The overexpression of DN-caspase-9 could effectively inhibit the 
BCR-induced fragmentation of nuclear DNA (Figure 11b.) and cleavage of caspase-3. However, 
BCR-induced Ψm collapse (Figure 11a.) and cell death measured by PI exclusion assay were only 
partly inhibited by DN-caspase-9 expression. Interestingly, the BCR-induced cytochrome c release 
was almost totally inhibited in DN-caspase-9 overexpressing cells, although the cytochrome c 
release has been previously suggested to be upstream of caspase-9 activation in the apoptotic 
cascade (III). 
   The release of cytochrome c and collapse of Ψm are regulated by a balance between pro-and anti-
apoptotic members of the Bcl-2 family (Kim et al., 2006; Willis et al., 2007). In consistent with this, 
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overexpression of Bcl-xL prevented both BCR-induced cytochrome c release and collapse of Ψm in 
HF1A3 cells. In addition, the BCR-induced DNA fragmentation, caspase-3 activation and cell death 
was blocked by Bcl-xL overexpression. Thus, we next asked if BCR-induced apoptosis was 
associated with the activation of pro-apoptotic members of the Bcl-2 family. We could not detect 
any changes in the expression level or intracellular location of pro-apoptotic Bim, Bik , Bad or Bax 
proteins after BCR triggering, although these proteins have been associated with BCR-induced 
apoptosis previously (Eldering et al., 2004; Jiang and Clark, 2001; Malissein et al., 2003; Takada et 
al., 2006). 
5.1.3 The caspase-8 activation pathway showed only marginal role in B cell receptor-induced 
apoptosis 
   The previous work has demonstrated that cross-linking of BCR induces an apoptotic pathway 
involving caspase-8 activation (Besnault et al., 2001). To study the role of caspase-8 activation 
pathway in BCR-induced apoptosis in our experimental model we generated a cell line 
overexpressing the long splice variant of cellular FLICE inhibitory protein, c-FLIPlong. Both the long 
and short splicing variant of c-FLIP interfere with caspase-8 activation at the death inducing 
signaling complex (DISC) (Krueger et al., 2001). HF1A3 cell were transduced with wild type c-
FLIPlong in IRES-GFP-lentivector or with IRES-GFP-lentivectror only (vector control).  
The overexpression of c-FLIPlong only marginally reduced the appearance of hypodiploid cells or 
Ψm collapse after BCR stimulation (Figure 11). The poor effect of c-FLIP overexpression on BCR-
induced apoptosis could not be explained by inadequate expression of c-FLIP, since Fas-induced 
DNA fragmentation and Ψm collapse were almost completely blocked in the same c-FLIPlong 
overexpressing cell line (Figure 11.). In concordance, the specific inhibitor of caspase-8 (z-IETD-
fmk) failed to inhibit BCR-mediated apoptosis while it effectively rescued cells from Fas-mediated 
apoptosis.  
Figure 11a-b. The effect of Bcl-xL, DN-caspase-9 and c-FLIPlong overexpression on receptor 
mediated apoptosis. The cells overexpressing Bcl-xL, DN-caspase-9 or c-FLIPlong were cultured 
with anti-IgG (3 μg/ml), rituximab (10 μg/ml) or anti-Fas (10 ng/ml) antibodies for 24 hours. Cells 
transduced with IRES-GFP-lentivector only were used as vector control cells. A) After culture, the 
cells were harvested for TMRM staining and flow cytometric analysis of cells with collapsed 
mitochondrial membrane potential (TMRM low cells). B) Cells were harvested for propidium 
iodide staining followed by analysis of cells with fractional DNA content by flow cytometry 
(hypodiploid cells). 
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5.2. The molecular mechanisms of Fas/CD95-induced apoptosis (II, III, IV) 
   Fas triggering in HF1A3 cells induced the cleavage and activation of caspase-8, which could be 
demonstrated by Western blot as an increase of the 18 kDa cleavage product and a decrease of the 
57 kDa full length caspase-8 (II). The specific inhibitor of caspase-8 activation, z-IETD-fmk, 
completely inhibited Fas-induced apoptosis showing the necessity of caspase-8 activation for the 
process (II). In line with this, the overexpression of both short and long splicing variants of c-FLIP, 
which interfere with caspase-8 activation at the DISC and thus inhibit caspase-8 activation, blocked 
Fas-induced apoptosis (Figure 11.) (IV). The activation of caspase-8 was followed by the activation 
of caspase-3 and fragmentation of nuclear DNA (II). The activation of caspase-9, the initiator 
caspase of the mitochondrial pathway, was unnecessary for Fas-induced apoptosis, since the 
overexpression of catalytically inactive DN-caspase-9 showed no effect on cell death (Figure 11.) 
(III). Fas-stimulation induced a profound release of cytochrome c and collapse of Ψm which could 
be inhibited by Bcl-xL overexpression (Figures 11.) (III). However, the overexpression of Bcl-xL 
showed no effect on Fas-induced activation of caspases -8 and -3, showing that the caspase 
activation was independent on the mitochondrial breach (III). In addition, the overexpression of Bcl-
xL only partly inhibited Fas-induced apoptosis as measured by DNA fragmentation (Figure 11.) (III) 
 
5.3. The molecular mechanisms of rituximab-induced apoptosis (IV) 
   Rituximab, the chimeric human-mouse mAb against the CD20 antigen, has been widely used in 
the therapy against follicular lymphoma. Rituximab has been shown to deplete malign B cells by 
three different and overlapping mechanisms: CDC, ADCC and apoptosis (Manches et al., 2003; 
Reff et al., 1994; Shan et al., 1998; van der Kolk et al., 2002). Binding of rituximab to the CD20 
surface antigen induces apoptosis by yet unknown mechanisms. Detailed knowledge of CD20-
induced signaling pathways to apoptosis may allow the development of more effective treatment 
modalities against B cell malignancies. 
   Propensity of various B cell lineages to undergo CD20-mediated apoptosis is highly variable 
(Chan et al., 2003; Manches et al., 2003). Sensitivity to rituximab-induced apoptosis has been linked 
with a maturational stage of a lymphoma progenitor cell (Mattila and Meri, 2008). This finding was 
also reproduced in our FL cell lines representing different maturational stages, as only one (HF1A3) 
of three available cell lines responded to rituximab treatment by apoptosis. The other cell lines, 
HF28 and H4.9, were resistant to rituximab-mediated apoptosis even when rituximab bound to 
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CD20 antigen was cross-linked by secondary antibody (anti-Fc -F(ab2)) (not shown). Although the 
use of cross-linking secondary antibodies against rituximab has augmented apoptosis in some 
experimental models (Stel et al., 2007; van der Kolk et al., 2002), in HF1A3 cells rituximab-induced 
apoptosis could not be enhanced by hyper-cross-linking. Instead, in HF1A3 cells, F(ab2) fragments 
directed against the Fc part of antigen receptor induced apoptosis itself. 
   The involvement of caspases in the rituximab-induced apoptosis has been controversially 
discussed. To explore the necessity of the caspase-9 and caspase-8 for rituximab-induced apoptosis, 
we developed cell lines in which the activity of these caspases was artificially blocked. The 
involvement of caspase-9, the initiator caspase of the intrinsic apoptosis pathway, was studied by 
using DN-caspase-9 overexpressing cells, in which caspase-9 was inactivated by a single amino 
acid mutation at the catalytic domain of the protease. The HF1A3 cells overexpressing FLIPshort and 
FLIPlong, natural inhibitor proteins of caspase-8 activation, were used to study the involvement of 
caspase-8 activation in the rituximab-induced apoptosis. According to our results, the caspase-9 
activation pathway was necessary for the rituximab-induced apoptosis, since blocking of the 
caspase-9 activation inhibited all apoptotic events induced by rituximab, including the activation of 
caspase-3, fragmentation of DNA (Figure 11b.), collapse of Ψm (Figure 11a) and release 
cytochrome c (IV).  In contrast, the caspase-8 activation pathway was dispensable for apoptosis 
induced by rituximab, since the overexpression of FLIP proteins showed no effect on rituximab-
induced apoptosis although in the same time Fas-induced apoptosis was totally abrogated by c-FLIP 
overexpression (Figure 11.).  
   Overexpression of Bcl-xL almost completely blocked the cytochrome c release and collapse of 
Ψm, showing that these changes were regulated by Bcl-2 family proteins (Figures 11.) (IV). In 
addition, rituximab-induced DNA fragmentation (Figure 11b.), collapse of Ψm (Figure 11a.), 
caspase-3 activation and cell death were also abrogated in Bcl-xL overexpressing cells. 
   The kinetics and magnitude of rituximab-induced apoptosis were substantially slower compared 
with Fas-induced apoptosis in the same cell line. After four days culture with rituximab, only about 
half of the cells were apoptotic. The slow induction of apoptosis may be partly explained by the fact 
that rituximab induces only a subpopulation of cells to undergo apoptosis at a time whereas the 
remainder of the cells may still proliferate and repopulate the culture. 
   The simultaneous culture with anti-Fas and rituximab antibodies showed an additive effect on 
apoptosis. The percentage of apoptotic cells increased from 15.9% +/- 1.7 (rituximab) to 38.3% +/- 
3.0 (rituximab combined with anti-Fas).  
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5.4. Molecular mechanisms of CD40-mediated protection against apoptosis (I, 
II and IV) 
    CD40 activation plays an important role in the regulation of B cell survival. In vivo, CD40 
receptor is activated by its natural ligand CD40L (van Kooten and Banchereau, 2000; Younes and 
Kadin, 2003). We studied CD40 signaling to reveal the signaling pathways involved in the anti-
apoptotic function of CD40. This knowledge could also be used in advantage in the study of 
receptor-mediated apoptosis. Another goal was to get insight how B cell survival is regulated in the 
germinal centers. The activation of the CD40 receptor was carried out by using an anti-CD40 
antibody AF1.15. The specificity of the AF1.15 antibody for CD40 receptor has been studied by 
immunoprecipitation (Pätäri A, 2000). CD40 stimulation could reverse apoptosis induced by Fas-
and B cell receptors (I, II), and in addition rituximab-induced apoptosis was inhibited by CD40 
stimulation (Figure 12.) (IV). 
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Figure 12. The effect of CD40 stimulation of receptor-mediated apoptosis 
HF1A3 cells were pre-treated two hours with anti-CD40 antibody or with medium only, followed 
by culture with anti-IgG (3 μg/ml), rituximab (10 μg/ml) or anti-Fas (10 ng/ml) antibodies. After 24 
hours culture, cells were harvested for propidium iodide staining and analysis of fractional DNA 
content by flow cytometry. The data presented is collection from three separate experiments. 
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5.4.1 Kinetics and signaling requirements of CD40 mediated protection from B cell receptor-
mediated apoptosis (I) 
   As presented above, BCR-induced apoptosis in HF1A3 cells was manifested by caspase-3 
activation, DNA fragmentation, cytochrome c release and collapse of Ψm. All these apoptotic 
events were completely blocked by CD40 stimulation. Interestingly, CD40 stimulation was able to 
protect from BCR-induced apoptosis up to 10 h from the induction of apoptosis. When CD40 
stimulation was done 12 h or later after the induction of apoptosis, its protective effect was 
gradually lost. 
   CD40 stimulation has been connected with the activation of the PI3-kinase, and mitogen activated 
protein kinases (MAPKs) P38 and ERK (van Kooten and Banchereau, 2000). In addition, the PKC 
activation pathway has been connected with B cell survival (Kronfeld et al., 2002). We used 
specific inhibitors of these pathways to study their role in CD40-mediated survival.  
Pre-treatment of cells with PI3-kinase inhibitor LY294002 had no effect on CD40-mediated 
protection from BCR-induced apoptosis. Similar results were also observed with specific ERK 
inhibitor PD 98059, Raf inhibitor ZM 336372, P38 inhibitor SB 203580 and PKC inhibitor Gö 6850 
(I).  
5.4.2 The CD40-induced protection against Fas-induced apoptosis was associated with a rapid 
up-regulation of anti-apoptotic c-FLIP (II) 
   As discussed above, activation of caspase-8 was indispensable for the induction of Fas-induced 
apoptosis. The Fas-induced cleavage and activation of caspase-8 was completely blocked by CD40 
stimulation, since the p18 active cleavage product of caspase-8 could not be detected when cells 
were pre-treated with CD40 before Fas stimulation. In addition, Fas-induced caspase-3 activation, 
DNA fragmentation, cytochrome c release and  Ψm collapse were blocked by CD40 stimulation. 
   The specific inhibitor of NF-κB activation, PDTC, was used to study the involvement of NF-κB in 
the anti-apoptotic signaling of CD40. When cells were pre-treated with PDTC before stimulation 
with Fas and CD40 antibodies, CD40 stimulation could no longer protect the cells from Fas-induced 
apoptosis. In addition, in the presence of PDTC, CD40 stimulation could not inhibit the Fas-induced 
caspase-8 activation. 
   Among other targets, transcription factor NF-κB regulates the expression of c-FLIP proteins, 
which can interfere with caspase-8 activation at the DISC (Krueger et al., 2001). Thus, we next 
studied if CD40 stimulation could induce c-FLIP proteins in our experimental model. CD40 
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stimulation induced a rapid upregulation of both long and short isoforms of c-FLIP, which could be 
seen at the mRNA within 2 hours and protein level within 4 hours after CD40 stimulation (II). The 
CD40-induced upregulation of c-FLIPshort/long mRNA and protein were completely blocked by 
PDTC, showing that the up-regulation of c-FLIP was dependent on the activation of NF-κB (II). 
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6. DISCUSSION 
6.1. FL cell lines as an experimental model for the study of receptor-mediated 
apoptosis 
   The cell line HF1A3 provides an excellent model for the study of receptor-mediated apoptosis of 
GC B cells, since the cells have retained the same immunophenotype and responses against 
physiological stimuli as their natural counterparts (Eray et al., 2003). However, although the cell 
line HF1A3 mimics germinal center B cells, the cells have genetic abnormalities such as Bcl-2 
overexpression, which may hinder cell death. We used the HF1A3 cell line to study receptor-
mediated selection of GC B cells. The findings presented here would be more easily generalized to 
normal GC B cells if we could replicate the results with primary GC B cells. However, the natural 
GC B cells die rapidly in vitro without growth support provided by their microenvironment, which 
makes it difficult to study apoptosis by using GC derived primary B cells. In addition, the cell 
transfection studies could only be conducted with stable cell lines, since large amount of cells is 
needed for the experimental procedure.  
   The cell line and the original patient sample have been carefully diagnosed according to REAL 
classification as follicular center cell lymphoma, a subtype of a follicular lymphoma (Eray et al., 
2003). Thus, the cell line offers a versatile tool for the pre-clinical study of FL directed cancer 
therapeutics. We used HF1A3 cell line for the study of molecular mechanisms involved in 
rituximab-induced apoptosis. Unfortunately, only one of our three FL cell lines was susceptible for 
rituximab-mediated apoptosis, and the other two cell lines (HF28 and HF4.9) were resistant. Thus, 
our findings concerning the molecular mechanism of rituximab-induced apoptosis, as well as BCR 
and Fas –induced apoptosis, need to be replicated in other B cell lines to generalize the results to all 
B cells. The establishment of FL cell lines has been demanding, and still over 10 years after their 
establishment, suitable human FL cell lines are not common. 
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6.2. Molecular mechanisms of receptor-mediated apoptosis  
6.2.1 Fas-induced apoptosis proceed via caspase-8 activation pathway while B cell receptor- 
and rituximab –induced apoptosis are dependent on mitochondrial pathway 
   As discussed earlier, two major apoptosis pathways have been classified; the death receptor 
(extrinsic) and mitochondria dependent (intrinsic) pathways. The death receptor pathway relies on 
the activation of the initiator caspase-8 at the DISC, followed by the activation of effector caspase-3 
(Medema et al., 1997). In mitochondria dependent (intrinsic) apoptosis, various apoptosis-inducing 
stress signals converge on mitochondria, resulting in the permeabilization of MOM, release of pro-
apoptotic IMS proteins and collapse of ΔΨm. The release of cytochrome c from IMS triggers the 
activation of caspase-9, an initiator caspase of the intrinsic pathway (Li et al., 1997). Commonly, 
the extrinsic pathway is engaged with the mitochondria-dependent pathway of apoptosis. In these 
cases, caspase-8 cleaves pro-apoptotic BH3-only protein Bid, and the truncated Bid translocates to 
mitochondria where it can promote MOMP and apoptosis (Li et al., 1998).  
   We used cell lines stably overexpressing Bcl-xL, DN-caspase-9 and c-FLIP to explore the 
involvement the death receptor (extrinsic) or mitochondrial (intrinsic) pathways in receptor- 
mediated apoptosis. As expected, Fas-induced apoptosis of HF1A3 cells showed typical 
characteristics of extrinsic apoptosis. Firstly, Fas-induced apoptosis was completely prevented when 
caspase-8 activation was blocked by a specific caspase-8 inhibitor z-IETD-fmk, or overexpression 
of either short or long splicing variants of c-FLIP. Secondly, Fas-induced apoptosis proceeded 
normally in cells overexpressing catalytically inactive form of caspase-9, which is an initiator 
caspase of the intrinsic apoptosis. Finally, Bcl-xL overexpression showed only 50% decrease in the 
amount of apoptotic (hypodiploid) cells, while Fas-induced cytochrome c release and collapse of 
ΔΨm were markedly inhibited in Bcl-xL overexpressing cells. In line with this, we showed that 
caspases were mainly activated upstream of mitochondrial breach in Fas-induced apoptosis. 
However, although mitochondria seem not be involved in the activation of caspases during Fas-
induced apoptosis, the mitochondrial breach may still enhance the cell death process. Loss of 
mitochondrial normal function leads to unbalanced Ca
2+
 release from the matrix, uncoupling of 
oxidative phosporylation leading to ATP depletion and superoxide production and acidification of 
cytoplasm due to anaerobic lactate production (Skommer et al., 2007). These events may ensure that 
the cell death is effectively completed. 
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   Apoptosis induced by BCR triggering and rituximab showed typical characteristics of intrinsic 
apoptosis since in the both forms of apoptosis mitochondria were centrally involved. 
Overexpression of Bcl-xL could inhibit cytochrome c release, collapse of ΔΨm and apoptosis 
induced by BCR triggering and rituximab, showing the importance of mitochondrial permeability 
change in apoptosis induced by BCR and rituximab. In addition, cells with catalytically inactive 
caspase-9, an initiator caspase of the intrinsic pathway, were resistant to DNA fragmentation 
induced by BCR and rituximab. Rituximab-induced apoptosis seemed even more dependent on 
caspase-9 activity when compared to BCR-induced apoptosis, since rituximab-induced cell death 
was almost completely prevented by DN-caspase-9 overexpression, while BCR-induced cell death 
was only partially inhibited. Our results are in line with a previous study showing that DN-caspase-
9 block completely BCR-mediated PARP cleavage, DNA laddering and caspase activation, while 
the cell death measured by PI exclusion decreased only about 50% (Herold et al., 2002). Based on 
our findings, we suggest that BCR-mediated cytochrome c release and collapse of ΔΨm may be 
induced in two phases, and only the second phase is mediated by caspase activation (see Figure 8. in 
the publication III). 
   Finally, overexpression of c-FLIP did not affect either BCR- or rituximab-induced apoptosis 
showing that the caspase-8 activation pathway was not involved. These findings are in variance with 
previous studies, which demonstrated that caspase-8 activation pathway was needed for BCR – and 
rituximab –induced apoptosis (Besnault et al., 2001; Stel et al., 2007). However, in these studies 
anti-IgM and rituximab were hyper-cross-linked by secondary antibodies, and it may be that in these 
circumstances extensive receptor cross-linking induces DISC-formation and caspase-8 activation. 
6.2.2 Feedback regulation of mitochondria by caspase-9 during intrinsic apoptosis 
   It has been widely accepted that during intrinsic apoptosis, MOMP allows the release of 
cytochrome c to the cytosol where it binds to Apaf-1 leading to formation of the caspase-9 
activating complex called the apoptosome (Riedl and Salvesen, 2007). Thus, it was rather 
unexpected to find out that both BCR- and rituximab -induced cytochrome c release was inhibited in 
DN-caspase-9 cells showing that caspase-9 regulated the release of cytochrome c from the 
mitochondria. This finding is in contrary to well documented view that cytochrome c release 
controls the caspase-9 activation (Zou et al., 1999), and not vice versa. Moreover, rituximab-
induced collapse of Ψm was completely dependent and BCR-induced collapse of Ψm was 
partially dependent on caspase-9 activation. Similarly, caspase-9 was demonstrated to control the 
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dexamethasone-induced collapse of Ψm in another FL cell line HF28 (Nuutinen et al., 2009). Thus, 
the caspase-9 mediated feedback regulation of mitochondrial breach seems to be a common 
phenomenon during the intrinsic apoptosis independent of the apoptotic insult, and not restricted to 
only one cell line. In line with this, a recent study showed that caspases-3 and -7 are involved in the 
collapse of Ψm and release of pro-apoptotic proteins, such as AIF, from the intermembrane space 
during intinsic apoptosis (Lakhani et al., 2006). In the same study cytochrome c release into cytosol 
was delayed in caspase-9 -/- mouse embryonic fibroblasts. The view that caspases can mediate Ψm 
collapse is supported by a finding that the respiratory chain enzymes are cleaved and inactivated by 
caspases during apoptosis (Ricci et al., 2004). Moreover, caspases can cleave and inactivate anti-
apoptotic members of the Bcl-2 family, including Mcl-1 and Bcl-xL, which can enhance the 
cytochrome c release and Ψm collapse during apoptosis (Chen et al., 2007). Thus, it is possible that 
also in our experimental model, caspase-9 and downstream caspases feed back to mitochondria by 
cleaving respiratory chain enzymes and anti-apoptotic Bcl-2 proteins. This feed back signaling to 
mitochondria may enhance apoptosis and ensure that the cell death process is effectively completed. 
   The conflicting results concerning the temporal ordering of cytochrome c release and caspase 
activation may be explained by the hypothesis that cytochrome c is released in biphasic fashion. 
Indeed, a previous study has shown that cytochrome c can be released from mitochondria at two 
distinct stages, the early cytochrome c activation being caspase-independent and late stage massive 
cyt c release being dependent on caspase activation (Chen et al., 2000). Thus, the first wave of 
cytochrome c release may be caspase-independent event which results from incomplete MOMP. 
This initial release of cytochrome c may be enough to activate the cascade of caspases which in turn 
may induce the complete release of cytochrome c. Indeed, it has been demonstrated that caspases 
can cleave and inactivate anti-apoptotic Bcl-2 family proteins and thus favor the release of 
cytochrome c to the cytosol (Chen et al., 2007; Cheng et al., 1997). 
   As a conclusion, caspases may have a more prominent role in the control of mitochondrial 
changes during intrinsic apoptosis than we have previously thought. We suggest that caspases may 
feedback on mitochondria to enhance mitochondrial deterioration during intrinsic apoptosis.  
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6.2.3. Caspase-9 –mediated apoptosis was poorly inhibited by pan-caspase-inhibitor z-VAD-
fmk 
   Interestingly, we found that the widely used pan-caspase-inhibitor z-VAD-fmk showed no effect 
on rituximab-induced apoptosis although apoptosis could be completely abrogated in the cells 
overexpressing DN-caspase-9. Similarly, BCR-induced DNA fragmentation was inhibited by DN-
caspase-9 overexpression but not by z-VAD-fmk. In the same time, z-VAD-fmk blocked 
completely DNA fragmentation and apoptosis induced by Fas showing that the inhibitor was 
functional. Thus, it seems that the pan-caspase-inhibitor z-VAD-fmk may not effectively inhibit 
caspase-9 activation while it is capable inhibiting other caspases such as caspase-8. In line with this, 
over-expressed caspase-9 has been shown to process caspase-3 even in the presence of z-VAD-fmk 
(Eldering et al., 2004). The poor effect of caspase-inhibitors against caspase-9 may be partly 
explained by the fact that the binding of the inhibitor may be hindered because the caspase-9 is 
buried in the apoptosome complex (Riedl and Salvesen, 2007). Based on these findings, the 
activation of caspases should not be assessed solely by using caspase-inhibitors.  
6.2.4. What happens before mitochondrial breach during intrinsic apoptosis?  
  We and others have demonstrated the several hours delay between the triggering of cell surface 
receptors and mitochondrial changes during intrinsic apoptosis (Mackus et al., 2002). What happens 
during this delay and how the signals originating from different apoptotic insults are integrated at 
the level of mitochondria are central questions of apoptotic research. It is widely accepted that pro-
apoptotic Bcl-2 family proteins Bax and Bak are centrally involved in MOMP and apoptosis, since 
cells deficient of both Bax and Bak have lost their susceptibility to MOMP and apoptosis (Wei et 
al., 2001). It is also generally accepted, that the BH3-only activator proteins can either directly or 
indirectly activate Bax and Bak (Kim et al., 2006; Willis et al., 2007). However, it is not known 
which pro-apoptotic Bcl-2 proteins are involved and how they are activated in apoptosis induced by 
BCR or CD20 stimulation.  
Previous studies with mouse immature B cell line have shown that BCR-induced apoptosis involves 
upregulation of proapoptotic Bcl-2 protein Bik and changes in Bad phosphorylation (Jiang and 
Clark, 2001; Malissein et al., 2003). In the other study, JNK dependent phosphorylation and 
activation of Bim was required for anti-IgM-induced apoptosis in mouse immature B cell line 
(Takada et al., 2006). In addition, BCR- induced apoptosis and deletion of autoreactive B cells was 
inhibited in Bim deficient mouse knock out model (Enders et al., 2003). However, the involvement 
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of Bim in human cell lines is not established as there may be differences in the involvement of 
apoptotic Bcl-2 proteins in mouse and men. Currently, there are no studies exploring the roles of 
Bcl-2 proteins during rituximab induced apoptosis. 
   The delay between BCR triggering and irreversible changes of apoptosis (caspase activation and 
mitochondrial breach) was several hours. Based on our studies with a protein synthesis inhibitor 
cycloheximide, we suggest that the delay enables a synthesis of new protein(s) which are 
responsible for the mitochondrial breach and induction of apoptosis. We took advantage of 2-D 
electrophoresis and mass spectroscopy to reveal if there was any BCR stimulation –induced changes 
in the protein composition of mitochondria. Unfortunately, we could not find out new apoptosis-
regulating proteins by using this method (unpublished). Neither could we ascertain the early signal 
transduction pathways originating from the BCR responsible for apoptosis.  
   Gene expression profiling has offered a new insight how apoptosis related gene expression can be 
studied. In a recent study, CLL cells responding to IgM triggering by proliferation showed increased 
expression of CD40, NF-κB and TRAF, which are associated with apoptosis inhibition (Guarini et 
al., 2008). In the contrary, CLL cells showing apoptotic response failed to express these survival 
genes, and it was concluded that the loss of survival signals leads to apoptosis in these cells. 
Induction of pro-apoptotic genes could not be detected in the same experiment. In another gene-
expression study specific genes related with BCR-induced proliferation and apoptosis was studied 
in Ramos cell line (Ollila and Vihinen, 2007). The study showed no increase in the genes associated 
with intrinsic pathway of apoptosis, while there was an induction of some genes involved in the 
death receptor pathway of apoptosis. Nevertheless, it has been demonstrated by previous studies that 
the death receptor (extrinsic) pathway is not involved in BCR apoptosis (Berard et al., 1999; 
Bouchon et al., 2000). Also in our studies, c-FLIP overexpression or the specific inhibitor of 
caspase-8 z-IETD-fmk failed to inhibit BCR-induced apoptosis, showing that the caspase-8 
activation pathway was not involved in BCR-induced apoptosis. As a conclusion, the identification 
of the proteins synthesized during apoptosis remains a central goal for future research. 
6.3. Molecular mechansims of CD40-mediated protection against apoptosis (I, 
II and IV) 
  The main function of CD40 is the regulation of T-cell mediated B-cell activation during humoral 
immune responses. CD40 activation promotes B cell proliferation, immunoglobulin production and 
class switching, GC formation and establishment of B cell memory (van Kooten and Banchereau, 
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2000; Younes and Kadin, 2003). Most importantly, CD40 activation is involved in the regulation of 
survival of both normal GC B cells and lymphoma cells. According to previous studies and our 
findings, CD40 stimulation can reverse apoptosis induced by Fas-, BCR-, CD20- and TRAIL-
receptors ((Cleary et al., 1995; Mackus et al., 2002; Merino et al., 1995; Metkar et al., 1998; Travert 
et al., 2008). In addition to TRAIL-induced apoptosis, apoptosis induced by dexamethasone and 
Doxorubisine was attenuated by CD40-stimulation in FL cells (Nuutinen et al. 2009, accepted for 
publication in Scand, J Immunol). 
   The signaling pathways responsible for anti-apoptotic function of CD40 are not completely 
understood. Among the earliest signaling events following CD40 stimulation are the activation of 
PI3K, MAPK P38 and Ras-Raf-1-ERK signaling pathways (Craxton et al., 1998; Gulbins et al., 
1996; Ren et al., 1994). However, these signaling pathways may not be the ones responsible for 
survival signaling of CD40. Based on our results, the specific inhibitors of PI3K, P38, Raf-1 and 
ERK could not inhibit the CD40-mediated rescue against BCR-induced apoptosis (I). Similar results 
were repeated in a recent study, where inhibitors of PI3K, MAPK, P38 and JNK could not block 
CD40-mediated rescue against TRAIL-induced apoptosis (Travert et al., 2008). 
   Accumulating evidence suggest that CD40-mediated survival is dependent on the activation of 
NF-κB family members p50, p65 (relA) and c-Rel (Andjelic et al., 2000; Berberich et al., 1994; 
Kreuz et al., 2001; Lee et al., 1999). NF-κB activation is at least partially mediated by a decrease in 
the half life of IκB-a and IκB-b proteins, which sequester NF-κB in cytosol in inactive form 
(Schauer et al., 1996). NF-κB is involved in the transcriptional control of several anti-apoptotic 
genes including c-FLIP (Kreuz et al., 2001), survivin (Granziero et al., 2001), Bcl-2 (Holder et al., 
1993), Bcl-xL and Bfl-1 (Lee et al., 1999). According to previous studies and our results, it seems 
that contribution of these different molecules to the CD40-mediated survival depends on the 
apoptotic insult. Whereas c-FLIP proteins may have a dominant role in the CD40-mediated 
protection against death receptor -mediated (extrinsic) apoptosis, the up-regulation of anti-apoptotic 
members of the Bcl-2 family plays substantial role in the CD40-mediated survival against 
mitochondria dependent (intrinsic) apoptosis (Kreuz et al., 2001; Lee et al., 1999) (Figure 13.).  
   Based on our findings, the CD40-mediated protection against death receptor -induced apoptosis 
was at least partly mediated by NF-κB dependent up-regulation of c-FLIP proteins. Firstly, the Fas-
induced apoptosis could be completely blocked by c-FLIP expression. Secondly, CD40 stimulation 
induced a rapid up-regulation of both c-FLIP proteins, and the c-FLIP up-regulation as well as the 
anti-apoptotic function was completely dependent on the activation of NF-κB. In concordance, c-
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FLIP proteins mediated also the anti-apoptotic function of CD40 against TRAIL-mediated apoptosis 
(Travert et al., 2008). However, in addition to c-FLIP, also other NF-κB dependent proteins, such as 
Bcl-xL, may be partly involved in the anti-apoptotic CD40 signaling against death receptor induced 
apoptosis.  It seems likely that CD40 stimulation induces a large array of protective molecules 
which can interfere with different steps in apoptotic pathways (figure 13). 
 
Figure 13. Molecular mechansims of CD40-mediated protection against apoptosis 
 
   CD40 stimulation induces the upregulation of c-FLIP, which interfere with caspase-8 activation 
during extrinsic apoptosis. Moreover, CD40 up-regulates anti-apoptotic Bcl-2 proteins, including 
Bcl-2 and Bcl-xL, which can stabilize mitochondrial membranes   Overexpression of c-FLIP proteins 
could not block mitochondria dependent apoptosis induced by rituximab or BCR-stimulation. 
Instead, the overexpression of pro-apoptotic Bcl-2 protein Bcl-xL potently inhibited both BCR and 
rituximab induced apoptosis. The pro-survival members of Bcl-2 family seem potential effectors of 
CD40-mediated action for several reasons. Anti-apoptotic Bcl-2 family proteins inhibit cytochrome 
c release and Ψm collapse by controlling mitochondrial membrane permeability (Kim et al., 2006; 
Kuwana and Newmeyer, 2003; Scorrano and Korsmeyer, 2003). In concordance, the overexpression 
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of Bcl-xL could inhibit BCR-induced Ψm collapse, cytochrome-c release and apoptosis in our 
experimental model. In addition, CD40 stimulation could increase the expression of Bcl-xL both in 
mRNA and protein level through NF-κB activation (Nuutinen et. al 2009, accepted for publication 
in Scand J Immunol). Bcl-xL may not be the only pro-survival Bcl-2 protein involved in the anti-
apoptotic action of CD40, and other proteins including Mcl-1 or Bcl-2 might also be involved. 
However, Bcl-2 alone seems not a very potent inhibitor of apoptosis, since the FL cells 
overexpressing Bcl-2 were still susceptible for apoptosis induced by different stimuli. 
. 
6.4. A proposed model of the molecular interactions during the germinal 
center negative selection 
   We studied the mechanisms of receptor-mediated apoptosis in the follicular lymphoma cell line 
HF1A3. Based on the morphology, immunophenotype and propensity to antigen-induced apoptosis, 
the cell line represents GC centrocytes undergoing negative selection (Eray et al., 2003). As in the 
case of HF1A3 cell line, cancer cells often retain the same immunophenotype and responses against 
physiological stimuli as their founder cells. Thus, the cell line offers a good model to study the 
signaling requirements of GC B cells undergoing the negative selection. On the other hand, the 
knowledge of the regulation of cell survival and death in GC can be used as an advantage for the 
development of new treatment modalities against B cell derived tumors, since normal GC B cells 
and lymphoma cells are similarly influenced by their GC microenvironment (Kuppers, 2004). 
   After the somatic hypermutaion of their Ig variable regions, centrocytes are subjected for selection 
on the basis of their antigen binding capacity (Figure 6.) The centrocytes with a high-affinity BCR 
are able to present antigen derived peptides in the contexts of MHC class II molecules for CD4+ 
helper T cells. Subsequently, the CD40 ligand is expressed transiently on the surface of helper T 
cells, and delivered for the centrocyte specific for the same antigen. The activating signal through 
both BCR and CD40 receptor selects the centrocyte for proliferation and differentiation in to 
antibody secreting cells. On the other hand, centrocytes that have became autoreactive during the 
SHM process are eliminated by the lack of proper T cell help, and die by apoptosis. Our findings 
support the previous view that BCR stimulus may be involved in the negative selection of self-
reactive cells (Billian et al., 1997), since the cells die by apoptosis after BCR stimulation without 
CD40 stimulus delivered within substantial time frame. The kinetics of BCR-mediated apoptosis 
strengthens this hypothesis, since there was over 12 hours delay between receptor activation and 
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irreversible changes of apoptosis. In addition, CD40 stimulation was able to reverse apoptosis up to 
10 hours after the BCR triggering. The time frame for CD40 rescue may be physiologically relevant 
because specific T cell help may not be immediately available after the BCR stimulus. Before the 
expression of CD40L is induced on the T cell surface, T cells have to be activated by interactions 
between the T cell and the centrocyte.  
   Since SHM is a random process, only few of the centrocytes improve their antigen binding 
capacity, whereas the majority of the centrocytes gain non-binding or non-functional receptors. 
Based on studies with Fas deficient mouse models (Hao et al., 2008; Takahashi et al., 2001), Fas-
induced apoptosis is centrally involved in the selection process of GC B cells. Thus, the centrocytes 
which have gained a low affinity BCR after the SHM may be eliminated by Fas-mediated apoptosis, 
which ensures a rapid deletion of these unnecessary cells. It has been suggested that GC B cells 
have a preformed CD95 DISC, in which caspase-8 activation is interfered by c-FLIP (Scaffidi et al., 
1999). Without survival signals provided by CD40- or antigen receptors or tropic factors from 
stromal cells, c-FLIP is rapidly degraded from the DISC leading to caspase-8 activation and 
apoptosis (Hennino et al., 2001; van Eijk et al., 2001). Thus, c-FLIP seems to be an important 
regulator of the positive selection in GCs. However, the B cells with improved antigen binding 
capacity which are rescued from Fas-induced apoptosis by c-FLIPlong expression may be still 
susceptible for BCR-induced apoptosis, which is implicated in the negative selection of self-reactive 
B cells (Billian et al., 1997). This suggestion is based on our findings that apoptosis induced by 
BCR triggering was only marginally inhibited by c-FLIPlong overexpression. 
   As a conclusion, the BCR stimulus may be involved in both negative and positive selection of 
centrocytes, and the T cell signals in the form of CD40 ligand discriminates between these fates. In 
addition, death receptor mediated apoptosis may be necessary for the elimination of low affinity 
centrocytes. The finding that Fas- and BCR -induced apoptosis use different signaling pathways 
may be physiologically relevant, since it enables that Fas- and BCR-induced apoptosis can be 
regulated independently, and targeted to different subsets of centrocytes. However, the hypothesis 
presented here need to be replicated in normal GC B cells, since the FL cell line used may have got 
genetic abnormalities during the long in vitro culture time, and thus not respond as original GC B 
cells. 
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7. CONCLUSIONS; Therapeutic applications and future directions 
 
   Cell surface receptors which regulate the live and death of lymphocytes are important in the 
regulation of normal B lymphocyte homeostasis. For example, extensive B cell proliferation must 
be balanced by elimination of extraneous or potentially harmful cells during the germinal center 
reaction. In addition to their importance in physiology, the cell surface receptors regulating cell 
death serve as attractive targets for cancer therapy. This work was devoted on the study of four cell 
surface receptors which are important in the regulation of B cell survival; B cell receptor, Fas/CD95 
and CD20 are receptors mediating apoptosis, and CD40 which regulates anti-apoptotic response 
against variety of apoptotic signals. 
7.1. Cell surface receptors in the regulation of life and death decisions in the 
germinal center 
    The first aim of the study was to explore the receptor mediated regulation of B cell survival 
during the germinal center reaction. The germinal center B cells die spontaneously in vitro without 
the growth support provided by GC microenvironment, and thus the mechanisms of receptor-
induced cell death is hard to study with the normal B cells. To circumvent this problem, we used a 
follicular lymphoma cell line HF1A3 as an experimental model. Based on the morphology, 
immunophenotype and propensity to antigen-induced apoptosis, the cell line represents GC 
centrocytes undergoing negative selection (Eray et al., 2003). As in the case of HF1A3 cell line, the 
malign cells often retain the same immunophenotype and responses against physiological stimuli as 
their founder cells. Thus, the cell line offers a good model to study the signaling requirements of GC 
B cells undergoing the negative selection. 
   Based on the existing literature and our findings of receptor mediated apoptosis, the following 
model of GC selection process can be depicted (see also Figure 6.). After the SHM, the centrocyte 
may have three different fates based on the antigen binding capacity of its newly formed antigen 
receptor. The few centrocytes with improved antigen binding capacity are positively selected as 
they get the CD40 survival signal from the antigen specific T cell due to effective antigen capture 
and presentation to the helper T cell. On the other hand, the centrocytes in which SHM has resulted 
non-functional or non-binding antigen receptor are negatively selected by the lack of T cell survival 
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signal CD40, and these cells are effectively eliminated by Fas-mediated apoptosis. The third fate of 
a centrocyte is to have an autoreactive antigen receptor. In these cells the activation of antigen 
receptor without a co-stimulatory CD40 signal leads to apoptosis. Thus, the signal from the B cell 
receptor is involved both in the positive and negative selection of a centrocyte, and the T cell help in 
the form of CD40 ligand discriminates between these fates. 
 The knowledge of the regulation of cell survival and death in GC can be used as an advantage for 
the development of new treatment modalities against B cell derived tumors, as the normal GC B 
cells and their malign counterparts are similarly influenced by their GC microenvironment 
(Kuppers, 2004). For example, the survival signals provided by activated T cells may counteract the 
cytotoxic effect of various chemotherapeutics, which may lead to resistance against cancer therapy. 
7.2. CD40-CD40L interactions as potential targets for cancer therapy 
   As demonstrated by our FL cell lines in vitro, CD40 activation counteracts apoptosis induced by 
cell surface receptors (Fas, TRAIL, CD20, BCR) and by chemotherapeutic agents (such as 
dexamethasone and doxorubisin). Similarly, CD40 ligation may counteract in vivo the action of 
various chemotherapeutics given to lymphoma patients, and thus generate resistance against cancer 
therapy. This resistance problem might be circumvented by development of CD40 blocking agents, 
which inhibit CD40-induced survival signaling. These CD40 blocking agents may function on the 
receptor level, such as antibodies which bind to CD40L blocking its activation. Another approach is 
to inhibit the downstream mediators of CD40 signaling. As demonstrated in this work, the most 
important mediators of CD40 signaling include the up-regulation of c-FLIP and Bcl-xL proteins 
which inhibit the death receptor-mediated and mitochondria-dependent apoptosis respectively. 
Attractive approach might be blocking of these proteins by siRNA method, in which the mRNA of 
these proteins is bound and cleaved specifically. Another approach might be the development of 
Bcl-xL small molecule inhibitors. Indeed, several small molecule inhibitors against another survival 
protein Bcl-2 are already developed and currently under clinical trials (Zeitlin et al., 2008). 
However, it should be mentioned that in addition to its pro-survival function in several low grade 
lymphomas, CD40 activation may be apoptotic signal in some more aggressive lymphomas and in 
these circumstances CD40 agonistic antibody is more practical choice. 
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7.3. Novel approaches to enhance rituximab therapy 
   Until these days, FL has been suggested as incurable disease as the therapies used showed no 
effect on the survival of FL patients. Introduction of rituximab has radically changed this view as its 
use in combination with chemotherapy has improved the live time expectancy of FL patients. 
However, still majority of the patients relapse after first line treatment. Thus efforts are being made 
to develop more efficient therapy against FL. 
   One of the aims of this work was to study the molecular mechanism of rituximab induced 
apoptosis. We demonstrated here the critical signaling events of rituximab-induced apoptosis in a 
FL cell, which is currently one of the most important targets of rituximab therapy in the clinics. The 
apoptosis induced by rituximab was dependent on the activation of caspase-9 and mitochondrial 
breach, while the death receptor pathway was not involved. Thus, drugs designed to destabilize 
mitochondrial membranes, such as BH3 mimetics or the antagonists of anti-apoptotic Bcl-2 
proteins, may be used in the future to enhance rituximab-induced apoptosis.  
   We showed also evidence, that the simultaneous triggering of the death receptor pathway by Fas 
enhanced significantly apoptosis induced by rituximab. The additive effect of simultaneous Fas and 
rituximab treatment on apoptosis may be a result of simultaneous activation of both the extrinsic 
(caspase-8-mediated) pathway by Fas and intrinsic (mitochondria dependent) pathway by rituximab. 
The death receptors appear as ideal targets for cancer therapy, as their activation directly leads to 
caspase-8 activation and initiation of the cell suicide program. The resistance against cancer therapy 
is most often associated with mutation of the tumor suppressor gene p53, and this resistance could 
be elegantly circumvented by death receptor mediated apoptosis, which can proceed independently 
of p53 activation. However, the use of FAS-ligand or Fas agonistic antibodies is not possible in the 
clinical settings due to the expression of Fas in hepatocytes and extreme hepatotoxicity 
demonstrated in mouse models (reviewed in (Yonehara, 2002)). To circumvent this problem, small 
molecules which can induce self-aggregation and ligand-independent activation of Fas receptor 
complex have been introduced. Of these molecules, edelfosine (ET-18-OCH) and perifosine can 
induce apoptosis in primary multiple myeloma cell line by recruitment of Fas receptor and 
downstream apoptotic signaling molecules into lipid rafts, leading to activation of the extrinsic 
pathway of apoptosis (Gajate and Mollinedo, 2007). Edelfosine is selectively taken up by cancer 
cells, and its therapeutic potential against B cell malignancies is currently being addressed in a 
phase II clinical study (Feller et al., 2005). In the future, it might be worth of studying the effect of 
edelfosine – rituximab combination therapy against FL in the clinical settings.  
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   In vitro studies have shown that rituximab-induced apoptosis was enhanced also by simultaneous 
activation of the death receptor TRAIL (Daniel et al., 2007). Activation of death receptors TRAIL-
R1 or -R2 by their ligands or agonistic antibodies induces death receptor pathway in cancer cells of 
different origin, including lymphoma cells (Younes and Kadin, 2003). TRAIL receptors are 
expressed predominantly on tumor cells making them excellent targets for cancer therapy. Several 
clinical trials investigating TRAIL as a potential anti-cancer drug are currently ongoing (Younes 
and Kadin, 2003). The efficacy and safety of TRAIL and rituximab combination therapy for NHL 
should be addressed in the clinical trial in the future. 
   Current trend in immunotherapy is the development of humanized antibodies which can be used in 
the treatment of hematological malignancies and inflammatory diseases. The infusion of humanized 
antibodies is associated with lesser side-effects caused by human anti-mouse-antibodies compared 
with chimeric antibodies. The progress in gene technology has enabled the production of humanized 
antibodies engineered to induce more efficient B cell depletion. For example, the humanized CD20 
antibody ofatumumab is more effective than rituximab in promoting the activation of complement 
dependent cell death (Pawluczkowycz et al., 2009). Another humanized CD20 antibody 
ocrelizumab is associated with higher antibody dependent cytotoxicity as compared with rituximab 
(Sikder and Friedberg, 2008). The tissue penetration of antibodies has been enhanced by the 
development of “small-weight antibodies”, which consist of only single heavy- and light -chain 
variable regions of human origin combined with engineered human IgG constant regions (Sikder 
and Friedberg, 2008).  Whether the novel humanized antibodies will supplant rituximab for 
treatment of hematological malignancies is currently being assessed by clinical trials. 
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